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INTRODUCTION 
 
DEFINITION 
 Bacterial keratitis is defined as an inflammatory infiltrate of the corneal 
stroma associated with an epithelial defect from which one or more bacterial 
species were cultured. 
CORNEAL  ULCERATION AS A CAUSE OF BLINDNESS 
1. Blindness continues to be one of the major public health problems in 
developing countries1 
2. According to  World Health Organization, corneal diseases are among 
the major causes of vision loss and blindness in the world today, after 
cataract and glaucoma1 
3. In India, it is estimated that there are approximately 6.8 million people 
who have vision less than 6/60 in at least one eye due to corneal 
diseases.  
4. According to the National Programme for Control of Blindness (NPCB) 
there are currently 1,20,000 corneal blind persons in the country. 
According to this estimate there is addition of 25,000 -30,000 corneal 
blindness cases every year in the country2. 
5. It is expected that the number of individuals with unilateral corneal 
blindness in India will increase to 10.6 million by 2020. 
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6. Corneal ulceration is a significant cause of corneal blindness .Corneal 
ulceration has been recognized as a silent epidemic in developing 
countries, especially the South-east Asian  Region. The causal factors 
responsible for corneal blindness vary with age.  
7. Significant causes of corneal blindness in adults residing in countries 
with less-developed economies are corneal scars (28.1%) and active 
keratitis (12.2%)1. 
8. In tropical countries like India Bacterial keratitis is the second most 
important cause of microbial keratitis next to fungal keratitis. 
REASON FOR THE STUDY: 
1. Bacterial keratitis is a serious ocular infectious disease that can lead to 
severe visual disability3. 
2. Once a bacterial corneal ulcer has been diagnosed, scraping of the ulcer 
for Gram stain evaluation, culture and sensitivity, and initiation of 
antibiotic therapy should follow in rapid succession9. 
3. The indiscriminate use of antibiotics has lead to the development of 
bacterial strains resistant to many commonly used agents(4,5) 
4. Over the last few years, there has been a major shift in the preferred 
topical antibiotic therapy for bacterial keratitis6. 
5. The spectrum of causative organisms and their susceptibility to 
antimicrobials varies according to the latitude and the degree of 
urbanization7 
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6. Periodic susceptability testing should be performed to ensure currently 
available antimicrobial are providing good coverage against recent 
clinical isolates of pathogenic bacteria5. 
NORMAL CORNEAL DEFENCE MECHANISM 
o There are several  defense mechanisms to protect the surface of the eye 
from many infectious agents . 
o Eyelids serves  as a physical barrier . 
o Mechanical flushing action of the tears is an important defense 
mechanism against infection due to presence of lysozyme, lactoferrin, 
beta-lysin and IgA antibodies10.  
o The mucin layer present in the tear flim can trap and remove potentially 
pathogenic organisms. 
o The normal ocular flora helps in preventing overgrowth of indigenous 
organisms or invasion of pathogens. 
o The conjunctiva contains sub-epithelial mucosal associated lymphoid 
tissue (MALT) with a collection of lymphoid cells having specific 
defensive functions. 
o The eye's acute non-specific inflammatory reaction to injury is mainly 
through phagocytosis of the invading neutrophils and later by 
macrophages, helping the immunocompetent host to control and destroy 
invading organisms. Specific hormonal and cellular reactions also 
countered opportunists. 
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RISK FACTORS 
EXTRINSIC FACTORS: 
 Use of contact lenses , especially  when associated with the following : 
o Overnight wear and long term use11. 
o Inadequate disinfection of contact lenses 
o Contamination of the contact lens storage container. 
o Infected or contaminated contact lens solution 
o Storage or rinsing contact lens  in tapwater 
 Trauma , including chemical and thermal injuries , foreign bodies , and  
local irradiation 
 Previous ocular and eyelid surgery ,mainly  corneal surgery including 
refractive surgery and penetrating keratoplasty. 
 Loose corneal sutures in keratoplasty 
 Medication related factors (e.g. contaminated ocular medications, 
topical NSAIDS, anesthetics, corticosteroids,  preservatives, glaucoma 
medications. 
 Immunosuppression (local and systemic) 
OCULAR SURFACE DISEASE 
 Tear flim deficiencies 
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 Abnormalities of the eyelid anatomy and their function (entropion, 
ectropion, blepharitis, trichiasis, lagophthalmos etc) 
 Adnexal infection/inflammation ( including gonococcal conjunctivitis, 
canaliculitis, dacrocystitis) 
CORNEAL EPITHELIAL ABNORMALITIES 
 Neurotrophic keratopathy 
 Disorders causing recurrent erosion of the cornea 
 Abrasion of cornea  or epithelial defect 
 Viral keratitis 
 Corneal  epithelial edema , especially bullous keratopathy 
SYSTEMIC CONDITIONS 
 Diabetes mellitus 
 Debilitating   illness especially malnourishment  
 Dermatological /mucous membrane disorders (e.g Steven- Johnson 
syndrome, ocular mucous membrane pemphigoid) 
 Immunocompromised status of the host 
ORGANISM FACTORS 
Virulence factors: 
  Infection of ocular surface tissues requires the microorganisms to 
attach, penetrate , invade, persist and replicate inspite  of many protective 
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mechanisms in the host12. The intact epithelial layer acts as a barrier that few 
pathogens can overcome. The organisms that can penetrate intact epithelium 
include Neisseria gonorrhoeae, Corynebacterium diptheriae, Haemophilus 
influenza, Listeria and Acanthamoeba. Other ocular pathogens require  
distruption of the epithelium for adherence and penetration. Virulence factors 
that favours tissue invasion include microbial exotoxins and proteases that 
destroy tissue cells , inflammatory cells and tissue matrix. 
INNOCULUM SIZE AND ROUTE  
The capability of the host's defenses determines the threshold of 
innoculum size at which infection is inevitable. Break in the epithelium is the 
most common route of entry  
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Table-1.1: CLASSIFICATION OF BACTERIAL OF IMPORTANCE IN 
MICROBIAL KERATITIS 
Gram-positive cocci(aerobic) 
Streptococcus pneumoniae 
CONS 
Staphylococcus aureus 
Staphylococcus epidermidis 
Enterococcus 
Micrococcus 
α, β, and  non hemolytic streptococci 
 
Gram positive bacilli(aerobic) 
Bacillus spp 
Corynebacterium spp 
Listeria monocytogenes 
 
Gram negative bacilli(aerobic) 
Pseudomonas aeruginosa 
Acinetobacter spp 
Enterobacteriaceae 
Klebsiella 
Serratia 
Proteus 
Citrobacter  
Escherichia 
 
Gram negative diplococci(aerobic) 
Neisseria 
 
Gram negative diplobacilli(aerobic) 
Moraxella 
 
Gram negative  
coccobacilli(aerobic) 
Haemophilus 
 
Gram positive cocci(anaerobic) 
Peptococcus 
Peptostreptococcus 
 
 
 
 
 
 
Gram positive bacilli(anaerobic) 
Propionibacterium acnes 
Actinomyces 
Clostridium(rare) 
 
Gram negative bacilli(anaerobic) 
Fusobacterium 
Bacteroides 
 
 
 
 
 
 
 
Gram negative cocci(anaerobic) 
Veillonella 
Spirochetes 
Treponema 
Borrelia 
Leptospira 
 
Gram positive filaments 
 Mycobacterium(non tuberculous) 
Nocardia 
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Fig-1.1: PATHOGENIC MECHANISM OF KERATITIS 
                     
 
 
 
1  
 
 
 
 
 
 
 
 
 
 
 
 
 
Breakdown of corneal defense 
mechanism 
Adherence, Replication and invasion of 
microorganisms 
Antigen 
response 
Compliment 
activation 
Antigen 
response 
Release of enzymes 
and exotoxins 
Polymorpho Nuclear Leukocute 
infiltration 
Release of 
lysosomal 
enzymes 
Oxidative burst 
with toxic 
metabolites 
Activation of 
corneal Lytic 
enzymes 
Suppurative corneal 
ulceration 
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PATHOLOGY OF CORNEAL ULCER 
 
The pathology can be divided into 3 stages: 
1.Stage of infiltration 
2.Stage of ulceration 
3.Stage of healing 
Stage of infiltration: 
 Tear flim and intact corneal epithelium act as effective barriers against 
invasion by organisms, which penetrate intact corneal epithelium are 
N.Gonorrhea, C.diptheria and H.influenza. 
The most common corneal pathogens like staphylococcus aureus, 
staphylococcus epidermidis, Pseudomonas aeruginosa  are known to posses 
adhesiveness to a breached epithelium. The glycocalyx helps in  adhesion of 
organisms to the epithelium13.  
Once the organisms gain entry via breached epithelium  they proliferate 
and invade stroma leading to swelling and necrosis which clinically cause a 
white or yellow lesion in the cornea. Infiltrate of acute inflammatory cells 
(mostly polymorphs) occurs following invasion of organism in the tissue. 
Necrosis of the tissue occurs due to the toxins and enzymes liberated by 
the organisms. Even after the death of microorganisms their  residues release 
endotoxins which can perpetuate inflammation. Toxins liberated by most  of 
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the bacteriae  and  in  case of pseudomonas having collagenolytic activity, 
which produces a protease, which can destroy the collagen. Polymorpho 
nuclear leukocytes liberate several toxins causing tissue damage.  Chemotaxis 
of leukocytes and their adherence and activation is by activation of 
complement cascade 
Stage of ulceration: 
             If infection is not controlled in infiltration stage   deeper stromal 
invasion occurs. There will be sloughing of epithelium and stroma leading to 
tissue loss creating  a crater. Margins of the crater are surrounded by edematous 
corneal epithelium and acute and chronic inflammatory cells  into the anterior 
chamber(hypopyon)14 
Stage of Repair: 
            In this stage both humoral and cellular immunity came in to action  
results in neutralization of organism by phagocytosing  them as well as the 
celluler debris. The corneal epithelium grows over the crater of the ulcer from 
its margin. A leash of blood vessels followed by  fibroblasts and macrophages 
encroach subepithelial space resulting in scar formation. Histopathologically 
post inflammation is suggested by fibrocytes with characteristic deep staining 
nuclei and cytoplasm with dense collagen fibers and absence of normal 
lamellar clefts14. Since Bowman's membrane is not capable of regeneration it is 
replaced by fibrous tissue. The stage of healing is complicated by keratectasia 
(forward protrusion of Descement's membrane) 
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Distinguishing features of specific bacteria: 
                   Classic bacterial ulcer is usually , sharply demarcated with an 
epithelial defect overlying a  stromal infiltrate with possible mucopurulent 
exudate , can be associated with surrounding edema and folds,  endothelial 
fibrin plaques, anterior chamber reaction , hypopyon . Symptoms are more than 
signs15.  
 
Fig 1.2 : Showing diagrammatic representation of bacterial corneal ulcer 
 
Staphylococcal ulcer: 
 Staphylococcal ulcer are more localized with minimal surrounding 
epithelial edema and stromal infiltrates. 
Pneumococcal ulcer: 
 Pneumococcal ulcer are deep oval central stromal ulcer with undermined  
edges and associated  hypopyon following trauma. Ulcer margin will have 
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serpiginous edge of activity thereby the ulcer progresses on one edge and heals 
on the other edge(15,16). 
Pseudomonas ulcer: 
                  Is most pathognomonic. It progress more rapidly can leads  to 
perforation and loss of eye in a short span of time. Blue yellow green purulent 
material may be adherent to ulcer surface. Diffuse epithelial graying  
(inflammation and  epithelial edema) is very characteristic16. 
Morexella ulcer: 
                   Is paracentral or perilimbal. As the organism is less virulent  
indolent ulcer, less destructive to corneal stroma and hence appearance is more 
grey than white. 
Gonococcal ulcer: 
 Gonococcal ulcer is associated with severe papillary conjunctivitis, 
chemosis and copious purulent discharge in a child with bilateral ulcer. 
 Ring abscess of cornea is associated with Ps aeruginosa, Proteus, 
B.cereus and Streptococcus. They most frequently occur following penetrating 
injury  at the limbus. 
 Streptococcus viridans causes an infectious crystalline keratopathy due 
to sheets of bacteria infiltrating between corneal lamellae. 
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Fig - 1.3 Showing Pseudomonas keratitis with hypopyon. 
 
 
 
 
 
Fig 1.4 Showing peripheral bacterial corneal ulcer with thinning. 
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Microbiological investigation:   
Smears: 
Grams stain 
10% KOH 
Media: 
Blood agar 
Chocolate agar 
Sabouraud's Dextrose agar 
Potato dextrose agar 
 
Optional smears and cultures: 
Giemsa stain 
Acid fast stain 
Lowenstein - jensen medium 
Non nutrient agar 
 
Collection and processing of samples: 
Conjunctival and lid swabs 
Corneal scrapings 
Corneal biopsy 
Anterior chamber paracentesis 
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Table-1.2 : Common media used in diagnosis of microbial keratisis 
Routine culture media Purpose 
Blood agar 
 
 
Chocolate agar 
 
 
Thioglycollate broth 
 
Supplemental media 
Lowenstein media 
Thayer martin agar 
Anaerobic blood agar 
 
Aerobic and Facultative , anaerobic 
bacteria including P.aeruginosa, 
S.aureus, S.pneumoniae 
Aerobic and facultative , anaerobic 
bacteria including H.influenzae, 
N.gonorrheae and Bartonella spp 
Aerobic and facultative , anaerobic 
bacteria. 
 
Mycobacteria, Nocardia 
Pathogenic Neisseria species 
Propionibacterium.acnes, 
Peptostreptococcus 
                             
Criteria for positive culture17: 
1. The growth of the same organism on two or more solid media on the C-
streak; semi-confluent growth at the site of inoculation on one solid 
medium, 
2. The same organism grown from repeated scrapings, 
3. The growth consistent with clinical signs, 
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4. Microscopy consistent with cultures- associated with the identification 
of the organism of appropriate morphology and staining characteristics 
on Gram or Giemsa stained corneal smears. 
Cultures for Staphylococcus epidermidis and Diphtheroids were 
considered positive only if there was moderate growth on at least two solid 
media. Liquid media are susceptible to contamination and so they could not be 
relied upon for accurately identifying organisms. 
 
Fig. 1.5 Showing growth of Steptococcus pneumoniae in blood agar 
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Fig. 1.6 Showing growth of CONS  in blood agar 
 
 
Fig. 1.7 Showing growth of Pseudomonas in blood agar 
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Determination of antimicrobial susceptibility: 
Standard disc diffusion or microdilution techniques are used to 
determine the antimicrobial susceptibility18. 
MIC and MPC in evaluation  of invitro antimicrobial potency and 
antibiotic resistance development18 
Minimum inhibitory concentration(MIC): 
MIC is an in vitro determination of the lowest concentration of a 
specific drug  that inhibits the growth of an organism at a defined inoculum of 
bacteria ( usually 105  colony forming units/ml) 18 
Mutant prevention concentration(MPC): 
MPC defines the drug concentration required to block the growth of 
organisms containing first step resistance mutations. 
MPC testing is relevant only with organisms that are determined to be 
susceptible to the antimicrobial agent by traditional susceptibility testing. 18 
Determination of MICs: 
The MIC of an antibiotic for a particular strain of bacteria is determined 
by standard microbiological agar and broth tests. 
MIC90 represents the antibiotic concentration that inhibits 90% of the 
isolates tested and is calculated when there are at least 10 isolates  of a 
particular microorganism(19,20). 
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MIC50 represents the antibiotic concentration that inhibits 50% of the 
isolates tested and is calculated when there are at least 5 isolates  of a particular 
microorganism21. 
In MIC tests surviving microorganisms are detected by their ability to 
produce visible growth either on a series of agar plates (agar dilution or agar 
diffusion methods) or in microtitre plate wells of broth (microbroth  dilution 
tests) 
Agar dilution method: 
In the agar dilution method, Petri dishes are filled with growth media 
containing various concentrations of antibiotic and solidified with agar. A 
defined amount of test organism is inoculated onto the top surface of the solid 
medium. After incubation at the proper temperature and atmosphere for 
approximately 18-24 hours the plates are screened for growth. The lowest drug 
concetration  preventing growth is the MIC18. 
Agar diffusion methods: 
In Kirby-Bauer disk diffusion test an antibiotic impregnated paper disk 
is placed on top of the agar that has been inoculated with bacteria. Alternatively 
a paper strip containing increasing concentrations of antibiotic is placed on top 
of the seeded agar(an E test)(17,18).  
For both kirby - bauer and E tests , the agar plates are incubated 
overnight to allow the bacterial inoculum to grow and form a continuous dense 
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film of growth on top of the agar except where growth of the bacterial isolate  
is inhibited by the antibiotic.  
This visible zone of inhibition around the disk is measured and the zone 
size is used to estimate the relative susceptibility or resistance of the organism 
to the antibiotic. The E test yields an actual MIC. 
The bacterial strain is reported as sensitive , intermediate or resistant 
depending on the zone size or the MIC  
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the penicillins and tetracyclines and most gram-negative facultative bacilli 
were susceptible to the tetracyclines or streptomycin22.  
In the 1950s and early 1960s, early-generation penicillins and 
streptomycin were popular choices for topical treatment of bacterial keratitis. 
Antibiotics, including cephalothin, cephaloridine, neomycin, erythromycin, 
lincomycin, colistin, and vancomycin, soon became available.  
In the 1960s, as penicillin resistance became common among S. aureus 
isolates, semisynthetic penicillins (e.g., oxacillin, nafcillin) and first-generation 
cephalosporins, such as cephalothin and cefazolin, all of which were resistant 
to staphylococcal beta- lactamases, became popular. 
At the end of the 1960s, gentamicin, a potent new congener of the old 
aminoglycoside, streptomycin, was introduced mainly for pseudomonas 
aeruginosa24. 
Over the next decade, other aminoglycosides, tobramycin and amikacin, 
were introduced. These aminoglycosides and first-generation cephalosporins, 
began to be used by ophthalmologists for the treatment of bacterial corneal 
ulcers. 
Although aminoglycosides are only modestly active against 
streptococci, including the pneumococcus, the high concentrations achieved in 
the tear film were adequate to treat keratitis, the use of fortified drops and 
periocular injections together with an agent, such as cefazolin, which is active 
against gram-positive cocci, offered good activity22. 
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Fig. 1.8 Showing disc diffusion in blood agar 
 
 
Fig. 1.9 Showing disc diffusion in Muller Hinton agar 
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Fig 1.10 : Showing Kirby - bauer disc diffusion method for  
culture sensitivity. 
 
An organism is defined as susceptible to an antibiotic if its MIC is 
below the serum break points. 
Pathogen is considered resistant to the antibiotic if the MIC is at or 
above the established breakpoint. 
Organisms demonstrate intermediate resistance if the MIC falls between 
the susceptible and resistant breakpoints. 
 
Evolution of antibiotics for bacterial keratitis: 
Sulfonamides were introduced in the 1930s and 1940s. Two of the 
congeners, sulfacetamide and trimethoprim are still used today23.  
 In the 1940s and 1950s, penicillin, streptomycin, and tetracyclines, 
became commercially available, followed by chloramphenicol, polymyxin, and 
bacitracin. Most cocci (gram-positive and gram-negative) were susceptible to 
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In the 1970s and 1980s, beta-lactams third generation cephalosporins  
were introduced to overcome the problems of resistant gram- negative bacterial 
infections and of aminoglycoside toxicity25.  
Some of these agents were used as “fortified” drops for the treatment of 
microbial keratitis .In the late 1980s manipulating  nalidixic acid ,like   
introduction of fluorine atoms on the molecules, led to drugs with much 
broader spectrums. An early congener, ciprofloxacin26, had great potency 
against gram-negative bacilli and H. influenzae but only moderate activity 
against S. aureus and modest activity against streptococci and pneumococci.  
The newest fluoroquinolones third generation such as levo- floxacin, 
fourth generation such as moxifloxacin and gatifloxacin have better potency 
than the older agents against gram positive cocci, pneumococci and are active 
against penicillin-resistant pneumococci.  
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Management of bacterial keratitis27:  
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Initial antimicrobials 
based on probable 
After 24 hrs, 
ulcer stabilizes 
After 24 hrs, 
ulcer worsens 
Continue RX Continue RX 
24-48 hrs 
Sensitive 
organism 
confirmed 
by culture 
24-48 hrs 
Resistant 
organism 
confirmed 
by culture 
24-48 hrs 
Ulcer 
stabilizes 
sensitive 
organism 
confirmed by 
culture 
24-48 hrs Ulcer 
continues to 
worsen resistant 
organism 
confirmed by 
culture 
Continue RX Continue 
RX Continue RX 
Modify  RX 
Ulcer 
sterilized 
Ulcer 
sterilized 
No 
improvement 
Reevaluate, 
consider 
alternative 
therapy, 
including 
possible 
surgical 
intervention 
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In two phases 
Sterilisation phase, 
Healing  phase . 
Sterilisation phase: 
Initial treatment should be intensive with hourly application of antibiotic 
so that the corneal tissue is rapidly saturated with  high antibiotic 
concentration. A high concentration (usually exceeding the minimum 
inhibitory concentration (MIC) by a number of log units) can be achieved 
within a few hours, so that 48 hours of sustained high concentrations is usually 
enough to eliminate most bacterial infections28. 
Sustained intensive treatment day and night for the ﬁrst 48 hours, hourly 
would allow for more than an adequate chance of sterilising the corneal ulcer. 
Healing phase: 
Following the initial treatment phase the antibiotic application is 
reduced to four times a day to allow for healing of the epithelial defect. 
Tapering the initial therapy offers no clinical advantage and is only 
likely to increase the likelihood of toxicity28.  
The healing phase may be prolonged for large culture positive ulcers, 
especially in the elderly who may also have ocular surface disease.  
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Common antibiotics active against  gram positive bacteria: 
Cephazolin(50mg/ml) 
Chloramphenicol(5-10mg/ml) 
Moxifloxacin 0.3% 
Vancomycin(15-50 mg/ml)   
Common antibiotics active against gram negative bacteria: 
Tobramycin(3-14 mg/ml) 
Gentamicin(3-14mg/ml) 
Amikacin(20mg in 0.5ml) 
Ceftazidime 
Ciprofloxacin(3mg/ml) 
Levofloxacin(3mg/ml) 
Ofloxacin(3mg/ml) 
Nocardia: 
Amikacin 2% 
Trimethoprim+sulfamethoxazole 
Atypical mycobacteria: 
Amikacin 2% 
Clarithromycin 1% 
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Fortification of antibiotics: 
Commonly fortified antibiotics: 
Cefazolin: 
  Add 5ml to 10ml distilled water or sterile saline to 500mg vial of 
cefazoline to obtain 10% or 5% solution. 
Vancomycin: 
  Add 10ml of distilled water or saline to 500mg vial of vancomycin and 
obtain a 5% solution. 
Amikacin: 
  Add 10ml of distilled water to 100mg of amikacin to get 1% solution. 
Gentamicin: 
  Add 2ml of injectable gentamycin to 5ml of commercial topical 
preparation to get 13.5mg/ml of fortified gentamicin. 
Adjuvant treatment: 
  Mydriatics and cycloplegics are used to prevent posterior synechiae. 
Steroids in severe inflammatory keratitis. 
Systemic antibiotics: 
Chance of Potential for systemic involvement( In N.meningitis, H. 
influenzae, N.gonorrhoeae infection) 
Severe corneal thinning and scleral involvement. 
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Signs of clinical improvement: 
Size and density of infiltrate and edema decreases, edema of the ulcer 
get blunted, anterior chamber reaction comes down and epithelilal and stromal 
healing begins. At this stage pupil dilates and hypopyon disappears. 
Other modes of treatment: 
Cyanoacrylate Glue: 
In sealing of small perforations and thin decemetoceles 
Conjunctival flap: 
Used for peripheral ulcers and also non healing central ulcers Excisional 
keratoplasty ,penetrating or deep lamellar keratoplasty: 
Non healing corneal ulcer in spite of appropriate and adequate 
antimicrobial therapy. 
  Impending perforation, 
  Perforated corneal ulcer. 
Complications of corneal ulcer: 
Descemetocele 
Perforation 
Anterior synechiae 
Secondary glaucoma 
Cataract 
Purulent iridocyclitis 
Endophthalmitis  
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REVIEW OF LITERATURE 
 
1. Bourcier et al conducted a retrospective analysis during 1998-1999 at 
France with 300 cases of bacterial keratitis. Potential predisposing factors, 
usually multiple, were identified in 90.6% of cases. Contact lens wear was 
the main risk factor (50.3%). Trauma or a history of keratopathy was found 
in 15% and 21% of cases, respectively and they concluded contact lens 
wear and trauma are the most important risk factors for bacterial keratitis29. 
2. Kaye et al in 2006 investigate the relationship between susceptibility of 
bacteria to topical antimicrobials and clinical outcome. MIC data were 
available for 421 patients, Sixteen (4%) patients required enucleation and 
23 (5%) surgical treatment; in 382 (91%) the ulcer healed with intensive 
topical antimicrobial therapy. There were signiﬁcant linear associations 
between clinical outcome and MIC for Pseudomonas spp. (P - 0.047), 
Staphylococcus aureus (P - 0.04), and Enterobacteriaceae (P - 0.045), but 
not for Streptococcus spp. (P - 0.85) and coagulase-negative staphylococci 
(CNS) (P - 0.88)30 
3. Jayahar et al analyse the invitro efficacy of commonly used antimicrobials 
against bacterial pathogens from corneal ulcers.  They evaluated 596 
patients  over 18 months period  September 1999 through March 2001. 
Antibacterial susceptibility of isolated bacteria were determined by the 
Kirby-Bauer disc-diffusion method  626 bacterial pathogens were isolated 
from 2596 corneal ulcer cases. 411(65.65%) were gram positive cocci. 
Streptococcus pneumoniae (41.85%) was the predominant bacterial species. 
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The antibacterial susceptibility was 451(72.04%) to cefazolin, 471(75.24%) 
to chloramphenicol, 321(51.28%) to cephaloridine,  430(68.69%) to 
vancomycin,564(90.09%) to ciprofloxacin; 429(68.53%) to norfloxacin; 
464(74.12%) to gentamicin and 202(32.27%) to cotrimoxazole. This study 
provides information on the efficacy of ocular antibacterials commonly 
used against bacterial pathogens of keratitis31.  
4. Srinivasan et al conducted randomized placebo controlled double masked  
clinical trial called SCUT (Steroids for corneal ulcer trial).This multicenter 
trial compared 1.0% prednisolone sodium phosphate to placebo  in the 
treatment of bacterial keratitis among 500 patients with culture positive 
ulcers  receiving 48 hours of moxifloxacin before randomization. The 
primary end point was 3 months from enrollment and 399 patients were 
evaluated at 12 months. The outcomes examined were best spectacle 
corrected visual acuity(BSCVA) and scar size at 12 months. They  
concluded that adjunctive corticosteroid therapy may be associated with 
improved long term clinical outcomes in bacterial corneal ulcers not caused 
by nocardia species32 
5. Chen et al conducted a retrospective analysis using samples and data 
collected in a pilot study conducted in preparation for the SCUT, to 
determine whether clinical outcomes in  bacterial keratitis are associated 
with antibiotic susceptibility. They observed MIC was associated with three 
month infiltrate/scar size each two fold increase in MIC was associated with 
a 0.33mm average diameter increase in scar size (P=.01). MIC was not 
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associated  with three month BSCVA (P=.71) or time to reepithelialization 
(P=.35) and they concluded that MIC was associated with infiltrate / scar 
size in bacterial keratitis33. 
6. Srinivasan et al in1994 conducted a clinical trial to determine the 
epidemiological characteristics and risk factors predisposing to corneal 
ulceration in Madurai to identify the specific pathogenic organisms 
responsible for infection. In 3 month period  434 patients with central 
corneal ulceration were evaluated. A history of previous corneal injury was 
present in 284 patients (65.4%). Cornea cultures were positive in 297 
patients (68.4%). Of those individuals with positive cultures 140 (47.1%) 
had pure bacterial infections, The most common bacterial pathogen isolated 
was Streptococcus pneumoniae, representing 44.3% of all positive bacterial 
cultures, followed by Pseudomonas spp (14.4%).They concluded central 
corneal ulceration is a common problem in south India and most often 
occurs after a superﬁcial corneal injury with organic material and most 
common organism causing bacterial keratitis is streptococcus 
pneumoniae34. 
7. Bharathi et al in 2007 conducted a retrospective analysis to identify the 
etiology , incidence and prevalence of ocular bacterial infection and to 
assess the ocular bacterial isolates to commonly used antibiotics. The most 
common bacterial species isolated were staphylococcus aureus, 
streptococcus pneumoniae , pseudomonas aeruginosa. According to this 
study gram positive cocci were the most frequent bacteria isolated from 
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ocular infections and were sensitive to moxifloxacin and vancomycin while 
gram negative isolates were more sensitive amikacin and gatifloxacin35 
8. Prajna Lalitha et al conducted a clinical trial to determine the emerging 
moxifloxacin resistance in pseudomonas aeruginosa isolates in South India 
during 2007, 2008 and 2009. They found a sharp increase in the proportion 
of resistant isolates from 19% in 2007 to 52% in 2009. They found a sharp 
increase in the proportion of isolates that were resistant to moxifloxacin  
from 2007 to 200936 
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AIMS AND OBJECTIVES 
 
 
1. To determine the bacteriological profile and sensitivity pattern of culture 
positive bacterial corneal ulcers in a tertiary care centre in a developing 
country 
2. To analyze the various risk factors and co morbidities associated with it 
3. To study the treatment outcome of culture positive bacterial keratitis  
  
 
 
 
METHODOLOGY 
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METHODOLOGY 
 
STUDY DESIGN: 
  This is a prospective  observational study where in all corneal ulcer 
patients attending the cornea clinic with culture proven bacterial keratitis were 
included according to inclusion and exclusion criteria 
 
DURATION: 
 One year of recruitment and three months of follow up,     
 1st December 2015  to 28th February 2017 
 
SAMPLE SIZE: 
 The sample size of minimum 92 patients will be need to include in the 
study with assumed percentage of success is 60% as per the clinical experience, 
and also assuming 10% precision error and 95% confidence interval. 
 
Formula:  
 
P          : Sensitivity of the new test 
d          : Precision 
Z1-α/2     : Desired confidence level 
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INFORMED CONSENT: 
 outcome of the treatment including various complications were 
explained to the patients in their own language and informed consent is 
obtained. patients were informed about the need for follow ups involved in the 
study.  
INCLUSION CRITERIA: 
 All culture  positive bacterial keratitis and who are willing to participate 
in the study will be included 
EXCLUSION CRITERIA: 
• Viral, fungal, acanthamoeba  and mixed keratitis. 
•  Culture negative keratitis. 
•   Mooren’s ulcers, marginal ulcers, interstitial   keratitis, sterile 
neurotrophic ulcers, and any ulcers associated with autoimmune 
conditions. 
•  Bacterial keratitis with impending perforation. 
• Perforated bacterial keratitis  
• Pre existing posterior segment pathology. 
• Patients not willing to participate in the study  
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HISTORY: 
 When included in the study all patient underwent a thorough workup. 
Patients 's age, gender and residence were recorded. A detailed history 
regarding the causative factor, mode of injury , systemic predisposing factor if 
any should be asked and recorded . An enquiry regarding duration of 
compliant, co-morbidity (Diabetes mellitus) , prior treatment or native 
medication if any should be done  
VISUAL ACUITY: 
 Unaided visual acuity was recorded by means of snellens chart kept at 6 
meter distance. In children following methods were used to determine the 
vision 
 <2 years- Picking up cake decoration 
 2-5 years-Sheridan Gardener chart 
In illiterate children and adults E chart is used. During every visit UCVA was 
tested and recorded 
CLINICAL PROCEDURES: 
  All patients with corneal ulcer attending the cornea clinic were 
examined under slit lamp biomicroscopy by trained ophthalmologist . 
Complete ocular examination were made with special attention to ulcer site 
(Entirely in periphery, Overlapping the corneal 4mm circle and periphery 
without filling the center, Entirely in the central 4mm circle, Completely filling 
4mm circle extending to periphery)37 is diagrammatically representated 
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according to the optscore, size (2mm,2-6mm, >6mm)17, depth of infiltrate (0-
33%,33-67%,67-100%)38 ,margin, edge and represented in diagram for further 
followup. Presence of hypopyon if any should be noted .Nasolacrimal duct 
patency and  random blood sugar is also checked.  After complete ocular 
examination and verbal consent from the patient, corneal scrapings were 
obtained for microscopic analysis and culture under aseptic precaution. 
Following instillation of 4% lignocaine corneal scrapings were obtained 
from the leading edge and base of the ulcer using heat steriled kimura spatula 
and was applied in even manner for 10%KOH and gram's stain in labelled glass 
slides, then for culture they were inoculated directly into blood agar in C 
shaped streaks and into Sabouraud's dextrose agar. 10% KOH wet mount 
preparation was examined immediately under microscopy mainly to identify 
the fungus. Other slide was stained using gram's iodine and examined under oil 
immersion lenses using 40X and 100X magnification and organisms were 
classified into 
Gram positive cocci 
Gram positive bacilli 
Gram negative cocci  
Gram negative bacilli 
Fungi 
No organisms 
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LABORATORY PROCEDURES: 
 All inoculated media were incubated at 37 degree celsius aerobically. 
These plates were examined daily for the growth. Criteria for culture positivity: 
1. Growth of same organisms on two or more solid media, semi confluent 
growth at the site of inoculum on one solid media 
2. Same organisms grown from repeated scrapings 
3. Growth is consistent with clinical signs 
4. Microscopy findings consistent with culture and morphology 
5. Others are considered negative and are exculded from the study 
SENSITIVITY PATTERN: 
 Positive bacterial cultures were sub cultured into Muller hinton agar for 
determination of sensitivity pattern. Sensitivity pattern were determined using 
disc diffusion method by measuring the zone of inhibition around the antibiotic 
disc and were interpreted as sensitive, intermediate and resistant according to 
Clinical and laboratory standards institute guidelines. 
MANAGEMENT: 
 Initial antibiotic therapy were started empirically according to gram 
stain report in addition to that topical cycloplegics and oral analgesics were 
also given if needed. Predisposing conditions if any like blockage in 
nasolacrimal duct, high blood sugar lagophthalmos, lid abnormalities etc 
should be corrected. 
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FOLLOWUP: 
Patients willing to participate in the study with regular followups were 
followed on regular intervals depending on the severity . On each followup 
UCVA with complete ocular examination done . Ulcer were studied for 
features of healing or worsening. During followup change in antibiotics if 
needed can be done according to sensitivity pattern and also by clinical 
response . Patients were followed in 3 weeks and at  3 months or till it heals 
whichever is earlier. ulcer is considered as improved when there is a blunting 
of edges, decreased density of  stromal infiltrate, decrease in stromal edema 
and endothelial plaque, decrease in anterior chamber reaction, reduction in size 
of hypopyon, re-epithelization , cessation in corneal thinning. 
  
  
 
 
 
RESULTS 
 
 
 
 
41 
 
RESULTS 
 
During the study period 2130 corneal ulcer patients attended cornea 
clinic, Out of which 969 patients were culture positive in which 26.4% (n=256) 
patients were bacterial culture positive. Out of 256 bacterial culture positive 
patients 55.4% (n=142) were gram positive organisms and 44.6% (n=114) were 
gram negative organisms. 
Table-4.1. Showing the analysis of  corneal ulcer in 
 2015-2016 
Total No. Of Corneal Ulcers 2130 
Total Number Of Culture Positive Corneal Ulcer 969 
Bacterial 256 
Fungal 685 
Total Number Of Gram Positive Organisms 142 
Total Number Of Gram Negative Organisms 114 
 
MICROBIOLOGICAL ANALYSIS : 
In our study out of 256 cases of bacterial culture positive keratitis about 
174 patients were enrolled for studying treatment outcome after exclusion by 
exclusion criteria. 
Among 142 gram positive organisms, 59% (n=84) were Streptococcus , 
8.4% (n=12) Staphylococcus , 16 were Corynebacterium , 9 were Coagulase 
negative Staphylococcus, 6 were Nocardia and 15 comprise of other organisms 
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Among 114 gram negative organisms grown in total bacterial culture 
(n=256), 69.2% (n=79) were pseudomonas, 11.2% (n=8) were moraxella., 
1.7% (n=2) were klebsiella, 3.3% (n=4) were acinetobacter. 
 
Table –4.2. Showing microbiological profile of  culture positive 
bacterial keratitis 
GRAM POSITIVE GRAM NEGATIVE 
1. Streptococcus sp ( n=84 ) 
2. Corynebacterium ( n=16) 
3. Staphylococcus (n=12) 
4. CONS (n=9) 
5. Nocardia (n=6) 
6. Others (n=15)  
1. Pseudomonas (n=79) 
2. Moraxella (n=8) 
3. Acinetobacter (n-4) 
4. Klebsiella (n=2) 
5. Others (n=21)  
 
 
 
Fig-4.1. Showing gram positive organisms in total culture positive 
bacterial keratitis in our study period 
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Fig-4.2. Showing gram negative organisms in total culture positive 
bacterial keratitis in our study period 
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SENSITIVITY AND RESISTANT PATTERN OF MOST COMMON 
ORGANISMS: 
Sensitivity and resistant pattern among organisms grown in culture of 
corneal scrapings were studied . Streptococcus species were most resistant to 
ciprofoloxcin and ofloxcin. most sensitive to 3rd generation fluroquinolones, 
cefazolin and vancomycin 
 
 
Fig-4.3: Showing sensitivity and resistant pattern of streptococcus species. 
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Table-4.3. Showing  sensitivity and resistant pattern of 
streptococcus species. 
ANTIBIOTICS SENSITIVE RESISTANT 
LEVOFLOX 82 1 
GATIFLOX 72 11 
MOXIFLOX 80 3 
CEPHOTAXIM 79 4 
CIPROFLOX 70 13 
OFLOXCIN 71 12 
CHLORAMPHENICOL 79 4 
CEFAZOLIN 79 4 
VANCOMYCIN 83 0 
TETRACYCLIN 75 8 
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Among 114 gram negative organisms grown in total bacterial culture 
(n=256), 69.2% (n=79) were pseudomonas . Pseudomonas species were most 
resistant to cephotaxim. Most sensitive to fluroquinolones. 
 
 
Fig-4.4: Showing sensitivity and resistant pattern of Pseudomonas species. 
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Table-4.4: Showing sensitivity and resistant pattern of 
Pseudomonas species. 
ANTIBIOTICS SENSITIVE RESISTANT 
LEVOFLOX 69 10 
GATIFLOX 68 11 
MOXIFLOX 69 10 
GENTAMYCIN 58 21 
TOBRAMYCIN 64 15 
CEPHOTAXIM 42 37 
CIPROFLOX 71 8 
OFLOXCIN 69 10 
AMIKACIN 62 17 
POLYMYXIN 69 10 
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DEMOGRAPHIC ANALYSIS: 
In our study out of 256 cases of bacterial culture positive keratitis about 
174 patients were enrolled for studying treatment outcome after exclusion  by 
exclusion criteria. In our study mean age of the patients were 54.55years 
 
 
Regarding sex ratio among 174 patients 109 were males and 65 were 
females 
 
Table-4.6 : Gender distribution among study population 
Sex n (%) 
Male 109 (62.64) 
Female 65 (37.36) 
Total 174 (100) 
 
 
 
 
 
 
 
Table -4.5 : Age distribution among study population 
Age (Years) 
n Mean (SD) Min - Max 
174 54.55 (19.04) 1 - 90 
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Fig- 4.5 : Gender distribution among study population 
 
 
Among 174 patients, categorised based on occupation.  About 65 
patients were farmers and 37 were manual labourers. These two categories of 
patients itself form above 60% of study population. Apart from this vegetable 
vendor ,carpenters  were affected from bacterial culture positive keratitis in our 
study. 
Table-4.7 : Occupation analysis among study population 
Occupation n (%) 
Agriculture 65 (37.36) 
Manual Labourer 37 (21.26) 
Vegetable Vendor 15 (8.62) 
Carpenter 9 (5.17) 
White collar job 3 (1.72) 
Others 45 (25.86) 
Total 174 (100) 
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Fig-4.6 : Occupation analysis among study population 
 
 
 
In our study mode of trauma was analysed. In which injury with dust 
and sand constitutes about 26.59%(n=46), which was the most common mode 
of injury in our study population. apart from this Thron, tree branches 
17.92%(n=31) and stick injury 17.92%(n=31)  were next common modes of 
injury. Other modes of injury for which patients presented in least percentages 
were vegetable matter , paddy , stone , metal instruments. 
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In our study patients who were taken traditional eye medication before 
initial presentation were analysed and data are as follows, 10.34% (n=18) used 
human milk , 6.90% (n=12) used castor oil, 2.87% (n=5) applied hens blood. 
About 74.71% (n=130) patients did not used any type of traditional medication 
 
 
 
 
 
 
 
Table-4.8 : showing mode of injury causing corneal ulcer. 
History of trauma n (%) 
Dust 46 (26.59) 
Thorn, Tree branches 31 (17.92) 
Vegetable Matter 18 (10.40) 
Stick 31 (17.92) 
Paddy 13 (7.51) 
Metal 7 (4.05) 
Stone 8 (4.62) 
Others 14 (8.09) 
No trauma 5 (2.89) 
Total 173 (100) 
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Table -4.9 : Traditional eye medication 
Traditional eye medicine n (%) 
Human milk 18 (10.34) 
Castor Oil 12 (6.90) 
Hens blood 5(2.87) 
Others 9(5.17) 
No traditional medication 130 (74.71) 
Total 174 (100) 
 
 
 
Fig-4.7 : Traditional eye medication 
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SYMPTOM ANALYSIS: 
In our study population most common presenting symptoms were 
studied among 174 patients. In which photophobia (n=130) ,redness (n=129) 
,blurring of vision (n=126) were most common symptoms followed by 
pain(n=121) and watering of eye(n=116). Most of the patients were presented 
with two or more above described symptoms. 
Table-4.10 : symptom analysis among study population. 
Symptoms 
Redness 
n (%) 
Photophobia 
n (%) 
Pain 
n (%) 
Watering 
n (%) 
Blurring of 
eyes 
n (%) 
Yes 
129 
(74.14) 
130 
(74.71) 
121 
(69.54) 
116 
(66.67) 
126 
(72.41) 
No 
45 
(25.86) 
44 
(25.29) 
53 
(30.46) 
58 
(33.33) 
48 
(27.59) 
 
Fig -4.8 : Symptom analysis among study population. 
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In our study duration in number of days taken by the patients to obtain 
tertiary care was studied. 78 patients consulted us within 3 days , 74 between 3 
to 7 days and 22 after 7 days.  
 
Table-4.11 : Duration of presentation among our study 
population 
Classification of duration n (%) 
0 to 3 days 78 (44.83) 
3 to 7 days 74 (42.53) 
Above 7 days 22 (12.64) 
Total 174 (100) 
 
Fig-4.9 : Duration of presentation among our study population 
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DIABETIC STATUS OF STUDY POPULATION:  
Number of patients with history of diabetes were analysed as poor 
glycemic control will hamper the corneal ulcer healing. In our study out of 174 
patients studied for treatment outcome 75 patients were diabetics and 99 were 
non diabetics. Also their current blood glucose levels were measured in terms 
of random blood sugar levels. Random blood sugar taken as high if the patients 
have value more than 200mg/dl. Out of 174 patients studied 40.80%(n=71) 
patients had high sugar levels and 59.20%(n=103) patients had normal levels 
 
Table-4.12 :  Incidence of diabetes mellitus in our study 
population 
Diabetes n (%) 
Yes 75 (43.10) 
No 99 (56.90) 
Total 174 (100) 
 
Fig-4.10 : Showing incidence of diabetes mellitus in our study population
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Table-4.13: Glycemic status at the time of initial presentation 
Random Blood Sugar n (%) 
High 71 (40.80) 
Normal 103 (59.20) 
Total 174 (100) 
 
Fig-4.11 : Showing glycemic status at the time of initial presentation 
 
 
CLINICAL ANALYSIS: 
In our study corneal ulcer site at the time of initial presentation was 
analysed. The site of corneal ulcer was categorised as follows with observed 
data . 
Patients presented with corneal ulcer entirely in the periphery were 
24.71% (n=43) , patients with ulcer overlapping the corneal 4mm circle and 
periphery without filling the center were 39.66%(n=69) . there are 
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circle and 12.07% (n=21) were had ulcer Completely filling 4mm circle 
extending to periphery. 
Table-4.14: Distribution of corneal ulcer 
Corneal Ulcer site n (%) 
Entirely in periphery 43 (24.71) 
Overlapping the corneal 4mm circle and periphery 
without filling the center 
69 (39.66) 
Entirely in the central 4mm circle 41 (23.56) 
Completely filling 4mm circle extending to periphery 21 (12.07) 
Total 174 (100) 
 
Fig -4.12 : Showing Distribution of corneal ulcer 
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On analysing the size of the culture positive bacterial corneal ulcer 
among study population, 16.09% (n=28) had ulcer size of less than 2mm , 
64.94% (n=113) had size of 2mm-6mm and  18.96%(n=33) of patients had 
ulcer size above 6mm. 
 
Table  4.15  : Size of culture positive bacterial corneal ulcer 
Ulcer size n(%) 
<2mm 28 (16.09%) 
2mm-6mm 113 (64.94%) 
>6mm 33 (18.96%) 
 
Fig- 4.13: Size of culture positive bacterial corneal ulcer 
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Depth of infiltrate in our study population of 174 patients were analysed 
according to the study protocol and were categorised as follows, 38.51%(n=67)  
patients had 0-33%  depth of infiltrate. 39.66%(n=69) having 33-67% of 
infiltrates and 21.84%(n=38) had 68-100% of infiltrates. 
 
Table –4.16: Depth of corneal infiltrate. 
Infiltrate n (%) 
0 to 33 % 67 (38.51) 
33 to 67 % 69 (39.66) 
67 to 100 % 38 (21.84) 
 
Fig-4.14: Showing depth of corneal infiltrate 
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In our study 13.29% of patients had  hypopyon associated with bacterial 
culture positive keratitis. 
 
Table-4.17: Corneal ulcer associated with hypopyon 
Hypopyon n (%) 
Yes 24 (13.79) 
No 150 (86.21) 
 
Fig-4.15 : Showing corneal ulcer associated with hypopyon. 
 
 
MANAGEMENT OF BACTERIAL KERATITIS: 
After gram stain report patients who are willing for giving consent and 
matching the inclusion and exclusion criteria were started on antibiotics based 
on clinical features and gram staining results. Data were as follows, 
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Table-4.18: Initial antimicrobials based on gram staining. 
Initial Antimicrobial n (%) 
Cefazolin 32 (18.39) 
Moxifloxcin 24 (13.79) 
Amikacin 5 (2.87) 
Tobramycin 9 (5.17) 
Gatifloxcin 3 (1.72) 
Chloramphenicol and polymixcin b 4 (2.30) 
Cefazolin + chloramphenicol + 
polymixcin b 
44 (25.29) 
Moxifloxcin+ chloramphenicol + 
polymixcin b 
26 (14.94) 
Amikacin + chloramphenicol + 
polymixcin b 
8 (4.60) 
Cefazolin + moxifloxcin 15 (8.62) 
Amikacin + moxifloxcin 1 (0.57) 
Gatifloxcin + Chloramphenicol + 
Polymixcin B 
3 (1.72) 
Total 174 (100) 
 
After initiation of empirical antibiotics based on gram stain reports 
patients were evaluated by clinical resolution of ulcer and culture sensitivity 
reports. Based on above evaluation change in antimicrobial therapy may be 
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instituted for certain number of patients. By which 31.03% (n=54) of patients 
needed change in antimicrobial therapy 
 
Table-4.19: Change in antibiotic according to culture and 
sensitivity pattern 
Change in antibiotic n (%) 
Yes 54 (31.03) 
No 120 (68.97) 
Total 174 (100) 
 
Fig-4.16 : Showing change in antibiotic according to culture and sensitivity 
pattern. 
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TREATMENT OUTCOME ANALYSIS: 
After 3 weeks of  treatment, patients were evaluated for  progress in the 
ulcer healing when compared to the initial presentation.  48.85% (n=85) of 
patients had improved outcome at 3rd week itself. 34.48% (n=60) had stable 
ulcer healing and 16.67% (n=29) had worsening of ulcer clinically. 
 
Table-4.20 : Ulcer healing at 3rd week 
Ulcer Healing at 3rd week n (%) 
Improved 85 (48.85) 
Stable 60 (34.48) 
Worsened 29 (16.67) 
Total 174 (100) 
 
Fig-4.17 : Showing Ulcer healing at 3rd week. 
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Treatment outcome is measured at the end of 3 months or complete resolution 
of corneal ulcer whichever is earlier. 79.89% (n=139) had favourable clinical 
outcome in means of ulcer healing and 20.11% (n=35) were not improved by 
means of ulcer healing. 
Table-4.21 : Ulcer healing at final follow up 
Ulcer healing at final follow up n (%) 
Improved 139 (79.89) 
Not Improved 35 (20.11) 
Total 174 (100) 
 
Fig-4.18 : Showing ulcer healing at final follow up. 
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ASSOCIATION BETWEEN DURATION OF PRESENTION AND 
ULCER HEALING: 
As duration of symptoms at time of initial presentation was analysed 
earlier in our study population it was compared with ulcer healing. Results 
were as follows – 82.05% (n=64) patients presented within 3 days of symptoms 
had good clinical outcome and  86.94% ( n=64 ) of patients presented between 
3 to 7 days were improved. Whereas only 50%(n=11) of patients presented 
after 7 days were improved clinical outcome 
 
Table-4.22 : Duration of initial presentation VS Ulcer healing at final 
followup 
Duration 
classification 
Ulcer healing at final follow up 
P value f Improved 
n (%) 
Not Improved 
n (%) 
Total 
0 to 3 days 64 (82.05) 14 (17.95) 78 (100) 
0.002 
3 to 7 days 64 (86.49) 10 (13.51) 74 (100) 
Above 7 days 11 (50.00) 11 (50.00) 22 (100) 
Total 139 (79.89) 35 (20.11) 174 (100) 
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Fig-4.19 : Duration of initial presentation VS ulcer healing at final 
followup 
 
 
 
ASSOCIATION BETWEEN DIABETICS AND ULCER HEALING: 
In our study ulcer healing in known diabetic individuals were analysed. 
In which, out of 75 diabetics 28% (n=21) patients corneal ulcer were not 
improved as per study criteria. Out of 99 diabetics 85.8% (n=85) were 
improved and 14.2% (n=14) were not improved as per study criteria. 
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Table-4.23: Diabetes mellitus Vs Ulcer healing at final followup. 
Diabetes 
Ulcer healing at final follow up 
P value c Improved 
n (%) 
Not Improved 
n (%) 
Total 
Yes 54 (72.00) 21 (28.00) 75 (100) 
0.024 No 85 (85.86) 14 (14.14) 99 (100) 
Total 139 (79.89) 35 (20.11) 174 (100) 
 
C - Chi Square test 
The above p value 0.024 (<0.05) shows that there is an association 
between diabetes and ulcer healing at the final follow up. 
 
Fig-4.20: Showing association between diabetes and ulcer healing  
at final followup. 
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ASSOCIATION BETWEEN ULCER SIZE AND ULCER HEALING AT 
FINAL FOLLOW UP: 
Among 28 patients with less than 2mm of ulcer size, 85.71% (n=24)of 
patients had improved ulcer healing and 14.28% (n=4) of patient had no 
improvement in ulcer healing. Among 113 patients with ulcer size between 
2mm and 6mm, 88.49% (n=100) shows improvement to the treatment and 
11.5% (n=13) shows no improvement. Among patients with ulcer size above 
6mm, 45.45% (n=15) shows improvement with treatment and 54.54% (n=18) 
shows no improvement at final followup. 
 
Table-4.24 : Ulcer size vs Ulcer healing at final follow up 
Ulcer size 
Ulcer healing at final follow up 
P value c 
Improved 
n (%) 
Not 
Improved 
n (%) 
Total 
<2mm 24 (89.55) 4(14.28) 28 (100) 
< 0.001 
2mm-6mm 100 (88.49) 13(11.5) 113(100) 
>6mm 15 (45.45) 18 (54.54) 33 (100) 
Total 139 (79.89) 35 (20.11) 174 (100) 
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Fig-4.21: Ulcer size vs Ulcer healing at final follow up 
 
 
ASSOCIATION BETWEEN DEPTH OF INFILTRATE AND ULCER 
HEALING. 
 As infiltrate size having major impact over final treatment outcome in 
cases of corneal ulcer we compared infiltrate size as per study definition to the 
final outcome in ulcer healing. 
 Out of 67 patients having 0-33% of  corneal infiltrates , 89.5% (n=60) 
had improved ulcer healing and 10.5% (n=7) were not improved in ulcer 
healing clinically. In 69 patients with 33-67% of infiltrates, 84.5% (n=58) were 
improved and 15.5% (n=11) were not improved. In 38 patients with extensive 
infiltrates 67-100% , 55%(n=21) were improved and 45% (n=17) were not 
improved. 
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Table-4.25 : Depth of infiltrate vs Ulcer healing at final follow up 
Infiltrate 
Ulcer healing at final follow up 
P valuec Improved 
n (%) 
Not Improved 
n (%) 
Total 
0 to 33 % 60 (89.55) 7 (10.45) 67 (100) 
< 0.001 
33 to 67 % 58 (84.06) 11 (15.94) 69 (100) 
67 to 100 % 21 (55.26) 17 (44.74) 38 (100) 
Total 139 (79.89) 35 (20.11) 174 (100) 
 
Fig-4.22: Showing association between depth of infiltrate and ulcer healing 
at final follow up 
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ASSOCIATION OF ULCER SITE AND UCVA AT FINAL FOLLOWUP: 
The association between the corneal ulcer site and UCVA at final follow 
up was analysed and results are as follows, in our study population of 174 
patients, 43 patients had ulcer at entirely in periphery, in which 40 patients had 
improved UCVA and only 3 patient’s UCVA was not improved.  
About 69 patients had ulcer Overlapping the corneal 4mm circle and 
periphery without filling the center ,56 patients had improved UCVA, 9 
patients had stable UCVA and 4 patients had worsened UCVA at final 
followup.  
In 41 patients with ulcer at Entirely in the central 4mm circle,35 patients 
had improved UCVA, 4 patients had stable UCVA and 2 had worsened UCVA. 
In about 21 patients who had ulcer Completely filling 4mm circle extending to 
periphery,13 patients had improved UCVA, 4 patients had stable UCVA and 4 
had worsened UCVA. 
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                                                          Table-4.26: Ulcer site vs UCVA 
Corneal 
ulcer 
1 line 2 lines 3 lines 4 lines 5lines Stable Worsened Total 
1* 34 
(79.07) 
6 
(13.95) 
0 
(0) 
0 
(0) 
0 
(0) 
1 
(2.33) 
2 
(4.65) 
43 
(100) 
2@ 32 
(46.38) 
12 
(17.39) 
8 
(11.59) 
2 
(2.90) 
2 
(2.90) 
9 
(13.04) 
4 
(5.80) 
69 
(100) 
3# 10 
(24.39) 
10 
(24.39) 
10 
(24.39) 
2 
(4.88) 
3 
(7.32) 
4 
(9.76) 
2 
(4.88) 
41 
(100) 
4$ 2 
(9.52) 
4 
(19.05) 
1 
(4.76) 
6 
28.57) 
0 
(0) 
4 
(19.05) 
4 
(19.05) 
21 
(100) 
Total 78 
(44.83) 
32 
(18.39) 
19 
(10.92) 
10 
(5.75) 
5 
(2.87) 
18 
(10.34) 
12 
(6.90) 
174 
(100) 
* ulcer at entirely in periphery 
@ ulcer overlapping the corneal 4mm circle and periphery without filling the center 
# ulcer at entirely in the central 4mm circle 
$ ulcer completely filling 4mm circle extending to periphery 
 
DIFFERENCE IN ULCER HEALING BETWEEN 3RD WEEK AND 
FINAL FOLLOWUP: 
Clinical outcome in ulcer healing between 3rd week presentation and 3rd 
month presentation were analysed. This analysis gives us the data regarding 
late response to the treatment due to change in antibiotics. None of patients 
who were improved during 3rd week had worsened healing. Out of 60 patients 
who had stable ulcer healing at the time of 3rd week, 65% (n=39) were 
improved and 35% (n=21) were not improved. Out of 29 patients who already 
had worsened clinical scenario at 3rd week , 51% (n=15) were improved and 
48.28% (n=14) were not improved. 
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Table-4.27 : Difference in ulcer healing between 3rd week and final 
followup 
Ulcer healing 
at 3rd week 
Ulcer healing at final follow up 
P value c Improved 
n (%) 
Not Improved 
n (%) Total 
Improved 85 (100) - 85 (100) 
< 0.001 
Stable 39 (65.00) 21 (35.00) 60 (100) 
Worsened 15 (51.72) 14 (48.28) 29 (100) 
Total 139 (79.89) 35 (20.11) 174 (100) 
 
Fig-4.23: Difference in ulcer healing between 3rd week and final followup 
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ASSOCIATION BETWEEN UCVA AND ULCER HEALING AT END 
OF THE STUDY: 
At end point of the study, patients UCVA and ulcer healing were studied 
and results are as follows, 
 In our study 139 patients were improved in corneal ulcer healing , in 
which 129 patients had 1 to 5 lines improvement in UCVA , 8 patients had no 
change in UCVA and only 2 patients had decrement in UCVA. But in cases in 
which ulcer is not healed, only 15 patients had improved UCVA of about 1-5 
lines and 10 patients had stable UCVA and 10 had worsened UCVA. 
 
 
 
 
 
 
 
Table -4.28  : UCVA vs ulcer healing at final followup. 
Ulcer 
healing at 
final 
follow up 
1  
line 
2 
lines 
3 
lines 
4 
lines 
5 
lines 
Stable Worsened Total 
Improved 
48.92 
(68) 
21.5
8 
(30) 
12.23 
(17) 
6.47 
(9) 
3.60 
(5) 
5.76 
(8) 
1.44 
(2) 
100 
(139) 
Not 
improved 
28.57 
(10) 
5.71 
(2) 
5.71 
(2) 
2.86 
(1) 
0 
(0) 
28.57 
(10) 
28.57 
(10) 
100 
(35) 
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Fig-4.24: UCVA vs ulcer healing at final followup. 
 
 
ANALYSIS OF UCVA AT INITIAL VISIT AND AT FINAL  
FOLLOW UP: 
 Visual acuity was recorded by snellens chart in all patients at initial and 
final followup. Snellen logMAR UCVA at final followup  shows 0.92± 0.51( 
mean±SD) which was significantly better than Snellen logMAR UCVA at 
initial followup 1.12 ±0.43. The above p value <0.01 shows that there is a 
significant difference between Initial VA and UCVA at final follow up. 
 
Table- 4.29:Analysis of UCVA at initial visit and at final follow up 
Parameter n Mean (SD) Min – Max P value^ 
Initial VA 174 1.12 (0.43) 0.18 – 2.6 
< 0.01 UCVA at final follow up 174 0.92 (0.51) 0.18 – 2.9 
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EFFECT OF CHANGE IN ANTIBIOTICS AND ULCER HEALING: 
 The effect of change in antibiotics over ulcer healing was analysed. In 
which out of 54 patients who had change of antibiotics during follow-ups 
64.81% (n=35) were improved and 35.19% (n=19) were not improved. 
Whereas out of 120 patients who did not had change of antibiotics during 
follow-ups, 86.67% (n=104) were improved and 13.33% (n=16) were not 
improved. 
Table-4.30 :Effect of change in antibiotics and ulcer healing 
Change in 
Antibiotic 
Ulcer healing at final follow up 
P value c Improved 
n (%) 
Not Improved 
n (%) 
Total 
Yes 35 (64.81) 19 (35.19) 54 (100) 
0.001 No 104 (86.67) 16 (13.33) 120 (100) 
Total 139 (79.89) 35 (20.11) 174 (100) 
 
Fig-4.25 : Effect of change in antibiotics and ulcer healing 
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DISCUSSION 
 
 The aim of our study is mainly to determine the bacterial profile, 
demographic characteristics and culture and sensitivity pattern and  treatment 
outcome in bacterial keratitis in a tertiary care centre. 
 Spectrum of causative organism and their susceptibility varies according 
to latitude. Indiscriminate use of antimicrobials had lead to emergence of many 
strains resistance to commonly used antimicrobials. 
 Hence periodic susceptibility testing should be performed to ensure 
currently available antibiotics are providing good coverage against recent 
clinical isolate of pathogenic bacteria. 
 Our study is a prospective observational study which include 174 
patients with culture positive bacterial keratitis 
MICROBILOGICAL ANALYSIS: 
 In our study with population of 174 patient with culture positive 
bacterial keratitis, gram positive organisms(n=142) were more than the gram 
negative(n=114).  
In gram positive organisms, streptococcus (59%) is the most common 
organism and Pseudomonas (69%) is the most common among gram negative 
This is in consistent with the study done by Jayahar et. al 31 
Streptococcus species were more sensitive to 3rd generation 
cephalosporins, 3rd  generation  fluroquinolones and vancomycin and most 
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resistant to old generation  fluroquinolone (ciprofloxacin, ofloxcin). 
Pseudomonas species were most sensitive to fluroquinolones like moxifloxcin 
and most resistant to cephotaxim. This is in accordance with the study done by 
Gangopadhyay et.al39 
Almost all organisms both gram positive and gram negative are sensitive 
to vancomycin except Nocardia. Out of 6 isolates, four were resistant  even to 
vancomycin but these are found to be more sensitive to aminoglycosides 
mainly amikacin. 
Methicillin resistance were prevalent among staphylococcus isolates, 
with many strains demonstrating multidrug resistance, most of them were 
found to be sensitive to vancomycin. 
DEMOGRAPHIC ANALYSIS: 
 In our study population which comprise of 174 patients, bacterial 
keratitis is more common among male than females. The mean age of 
presentation in our study is about 54.5 which comprise mainly of  working 
population. This shows occupational exposure is one of the leading cause of 
bacterial keratitis. 
 Most common mode of injury in our study population is exposure to 
dust 26.59% (n=46) followed by thorn and vegetable matter. This is in relevant 
to the study done by Srinivasan et. al34 
 Among 75 diabetics, 28% (n=21) did not improved at final followup 
whereas out of 99 non diabetics only 14.14% (n=12) shows no improvement at 
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final followup. This shows that diabetes mellitus is one of the confounding 
factors between the bacterial keratitis and its treatment outcome. Among 174 
patients 74% of patients did not had any type of traditional eye medications. 
Among 26% of traditional medication users human milk and castor oil user 
were majority in number after which comes hens blood users. 
 In our study among 152 patients who presented with in a week, 80-86% 
showed good improvement in ulcer healing at final followup whereas only 50% 
of 22 patients who presented late after a week showed improvement to the 
treatment at final followup. This concludes patients who seeks early 
consultation at tertiary center have a better outcome when compared to others. 
This is in consistence with bourcier et al3 
CLINICAL PROFILE AND TREATMENT OUTCOME: 
 In our study the impact of clinical profile over the treatment outcome 
were analysed and are statistically significant with p value <0.05. Regarding 
ulcer size, only 10-15% had got poor treatment outcome among 141 patients 
presented with <6mm ulcer size. Whereas 54.54% of patient had poor outcome 
when ulcer size is >6mm. This shows there is a linear relationship between the 
ulcer size and the treatment outcome. This is already stated by Stephen kaye et. 
al. Like this patients with deep stromal infiltrate had poor treatment outcome in 
our study. Patients with deeper infiltrates of  >67% only 55% of patients had 
improved clinical outcome. 
 When site of corneal ulcer and UCVA at final follow up was analysed, 
patients with peripheral ulcer had good improvement in UCVA. And patients 
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who had ulcer more in the center had poor improvement in UCVA. This 
analysis is statistically significant with P value of  <0.01 (Fisher’s exact test). 
 Association among patients who had change in antibiotics during follow 
up and their treatment outcome in terms of ulcer healing were analyzed.  
Among 54 patients who had change in antibiotics during their treatment 
35.19% had poor prognosis whereas patients who responded to initial 
antibiotics had only 13.33% of poor treatment outcome. This analysis is 
statistically significant with P value of <0.001. 
In our study,  patients who improved before 3 weeks shows good 
treatment outcome at final followup. whereas 30% of patients who had stable 
or worsened ulcer healing at 3rd week showed poor treatment outcome at final 
follow up.   
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CONCLUSION 
 
 In our study population with male predominance , Streptococcus is most 
common among gram positive which is most sensitive to cephalosporins 
and 3rd generation fluroquinolones . Pseudomonas is the most common 
gram negative organism which is  most sensitive to fluroquinolones. 
  Hence from our study  patients with corneal ulcer if gram's stain results in 
Gram positive most suitable antibiotic will be cephalosporins and 3rd 
generation fluroquinolones and in cases of Gram negative patients should 
be started on empirical antibiotics which includes 3rd generation 
fluroquinolones. 
 Initial empirical antibiotics has important role in defining the final 
treatment outcome. In our study  patients who had change in antibiotics 
which is not sensitive to initial one had increased risk of  poor treatment 
outcome. 
 Among co-morbidities , Patients who had diabetes mellitus shown to have 
poor treatment outcome when compared to non diabetic individual. 
 From our study it is studied that the treatment outcome is also well 
influenced by the corneal ulcer characters at the time presentation. Corneal 
ulcer with following characters had poor outcome in our study 
o central ulcer had poor outcome in UCVA 
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o larger ulcer with size >6mm and infiltrate depth >67% had poor 
ulcer healing. 
 Following were the predictors of poor outcome of culture positive 
bacterial keratitis 
 Patients who presented late ( >7 days ) 
 Patients who had high / uncontrolled glycemic levels 
 Patients with traditional eye medication 
 Patients who needs change in antibiotics either for clinical 
deterioration or according to sensitivity results 
 Patients with central, larger and deeper corneal ulcer. 
Hence patients with above clinical characteristics should be followed up 
regularly. By doing which the morbidity and preventable blindness can be 
decreased. 
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study, procedures and treatments for the above study and have 
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answers to all of my questions.  I have been given a copy of 
the informed consent form to take home  
[         ]  
I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being affected. 
However, this is may  not be possible for certain surgical 
procedures  
[         ]  
I understand that the Investigator of the study to access my 
health records for the research purpose. However, I understand 
that my identity will not be revealed in any information 
released to third parties or published.  
[         ]  
Informed Consent form to participate in a clinical trial 
Study Title- sensitivity pattern and treatment outcome in 
culture positive  bacterial keratitis 
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Subject’s Name: _______________Subject’s Initials: _______________     
Subject ID No: _________________     
Date of Birth / Age: _________________ 
9 
 
I agree not to restrict the use of any data or results that arise 
from this study provided such a use is only for scientific 
purpose(s)  
[         ]  
 
 
 
 
 
 
 
Signature (or Thumb impression) of the Subject: 
_____________________________     
Date: _____/_____/______ 
Subject’s Name: ___________________________________________ 
  
Signature (or Thumb impression) of Legally Acceptable Representative (LAR): 
_________________________________              Date: ____________  
Signature of the Investigator: ___________________________ 
Date: _____/_____/______ 
  
Investigator’s Name: 
__________________________________________________ 
 Signature of the Witness ______________________               
Date:_____/_____/_______  
  
Name of the Witness: 
_______________________________________________________ 
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EVALUATION FORM 
PATIENT DETAILS:      Date:  
Name: 
Age: 
Gender:    1.Male     2.Female  
Address and contact no: 
MR number: 
Study sample number: 
Occupation: 
1. Agriculturist 
2. Manual labourer 
3. Vegetable vendor 
4. Carpenter 
5. White collar job 
6. House wife 
7. others 
PRESENT HISTORY: 
Eye involved:        RIGHT   LEFT  
H/o trauma:   YES    NO 
Mode of injury: 
1. Dust 
2. Thorn 
3. Vegetable matter 
4. Stick 
5. Paddy 
6. Metal 
7. Stone 
8. Others 
9. none 
Duration in days (from onset to day of presentation):  
Any H/o Traditional eye medicine :    
1. Human milk 
2. Hens blood 
3. Castor oil 
4. Vegetable juice  
5. others 
Any H/o previous ocular medications:   
1. Antibiotics 
2. Antifungals 
3. Antivirals 
4. Steroids 
5. Others 
H/o contact lens usage:  1.Yes      2.No 
Previous ophthalmic history: 
1. Corneal disease   ………………………………………………  
2. Uveitis    ……………………………………………… 
3. Dacrocytitis   ……………………………………………… 
4. Eye surgeries   ……………………………………………… 
5. Others    ……………………………………………… 
 SYSTEMIC HISTORY: 
1. Diabetes    6.  Others  
2. Malnutrition    7.  None 
3. Immune-suppression 
4. leprosy 
5.  Neurological disorders  
OCULAR EXAMINATION:  
EXAMINATION RIGHT EYE LEFT EYE 
 
SNELLEN’S 
CHART 
UCVA 
  
BCVA 
  
LIDS 
1. Normal 1. Normal 
2. Edema 2. Edema 
3. Blepharitis 3. Blepharitis 
4. Trichiasis 4. Trichiasis 
5. Dry eye 5. Dry eye 
6. Lagophthalmos 6. Lagophthalmos 
7. Entropion 7. Entropion 
8. Ectropion 8. Ectropion 
9. Others 9. Others 
CONJUNCTIVA 
1. Congestion 1. Congestion 
2. Edema 2. Edema 
3. Discharge 3. Discharge 
4. Others 4. Others 
  
ANTERIOR 
CHAMBER 
1. Quiet Yes No Yes No 
2. AC cells 0 0.5+ 1+ 2+ 3+ 4+ 0 0.5+ 1+ 2+ 3+ 4+ 
3. AC flare 0 1+ 2+ 3+ 4+  0 1+ 2+ 3+ 4+  
 
 
4. Hypopyon 
Yes 
Vertical 
height 
………mm 
 
 
No 
 
Yes 
Vertical 
height 
………mm 
 
 
No 
IRIS IRITIS Yes No Yes No 
PUPIL 
Shape : Shape : 
Size : Size : 
1. RTL 1. RTL 
2. SRTL 2. SRTL 
3. NRTL 3. NRTL 
4. RAPD 4. RAPD 
LENS 
1. Normal 1. Normal 
2. Abnormal 
……………………………. 
2. Abnormal 
………………………….. 
FUNDUS 
1. Deferred 
2. Normal 
3. Abnormal 
     .………………………… 
1. Deferred 
2. Normal 
3. Abnormal 
……………………… 
DESCRIPTION OF CORNEAL ULCER: 
 
1. Site of the corneal ulcer:   ……….mm from the limbus 
2. Size of the corneal ulcer:   ……..mm 
3. Epithelial defect:    ……..mm 
4. Infiltrate:  1.YES  ………………mm    2.  NO 
5. Depth of ulcer: 
1. Superficial 
2. Deep  
3. Impending perforation 
4. Perforated  
6.   Margins of ulcer:   
7.   Stromal edema  1. YES         ………………..mm  2.  NO  
8.   DM fold   1. YES      2.  NO 
7.   Corneal sensation:  1. NORMAL  2.DIMINISED  3.ABSENT 
8.   IOP by digital tonometry : 1. NORMAL  2.INCREASED  3.DECREASED 
9.   Duct  of the affected eye: 
1. Free 
2. Not free with clear fluid 
3. Not free with pus  
4. None 
  
LABORATORY RESULT 
1.SMEAR/ GRAM STAIN: 
1. GPC 
2. GPB 
3. GNC 
4. GNB 
5. FUNGI 
6. NONE 
2.10% KOH 
1. POSITIVE 
2. NEGATIVE 
3.CULTURE AND SENSITIVITY REPORT 
1. Date of culture performed 
2. Were organism grown in the culture 
3. If yes  1. Mild  2. Moderate   3. Heavy   4.None 
4. Organism : …………………………………………………….. 
 
 
 
 
CULTURE AND SENSITIVITY REPORT 
 
 
Sl.No 
Gram Positive Cocci in pairs 
 
(Streptococcus species) 
 
Gram positive cocci in groups 
 
(Staphylococcus species) 
 
 
Gram Positive Bacilli 
 
(Nocardia, Bacillus spp 
& Corynebacterium spp) 
 
1 Chloramphenicol Chloramphenicol Chloramphenicol 
2 Cefazoline Cefazoline Cefazoline 
3 Cephotaxime Cephotaxime Cephotaxime 
4 Ciprofloxacin Ciprofloxacin Ciprofloxacin 
5 Cefuroxime  Ofloxacin Ofloxacin 
6 Gatifloxacin Gatifloxacin Gatifloxacin 
7 Levofloxacin Levofloxacin Levofloxacin 
8 Moxifloxacin Moxifloxacin Moxifloxacin 
9 Ofloxacin Vancomycin Vancomycin 
10 Oxacillin - for Pneumococci Gentamycin Gentamycin 
11 Optochin / Bacitracin Tobramycin Tobramycin 
12 Penicillin Tetracycline Nocardia spp - Ceftazidime 
13 Piperacillin/Tazobactam Oxacillin Nocardia spp - Amikacin 
14 Tetracycline Cefoxitin Nocardia spp - Co-trimoxazole 
15 Vancomycin Penicillin 
 
CULTURE AND SENSITIVITY REPORT 
 
 
Sl.No Atypical mycobacterium Pseudomonas species 
 
Gram Negative Bacilli  
 
other than 
Pseudomonas spp. 
1 
Amikacin Amikacin Amikacin 
2 
Choramphenicol Ceftazidime Ceftazidime 
3 
Cefazolin Cephotaxime Cephotaxime 
4 
Ceftazidime Ciprofloxacin Ciprofloxacin 
5 
Cephotaxime Ofloxacin Ofloxacin 
6 
Ciprofloxacin Gatifloxacin Gatifloxacin 
7 
Ofloxacin Levofloxacin Levofloxacin 
8 
Gatifloxacin Moxifloxacin Moxifloxacin 
9 
Levofloxacin Gentamycin Gentamycin 
10 
Moxifloxacin Tobramycin Tobramycin 
11 
Gentamycin Polymixin B Polymixin B 
12 
Tobramycin 
 
Tetracycline 
13 
  Cefazoline 
14 
  Chloramphenicol 
15 
  
Haemophilus spp - 
Ampicillin 
TREATMENT 
 
 
1. Empirical antibiotic:……………………………………………………………………… 
2. Dosage of empirical antibiotic:…………………………………………………………… 
3. No. of days given:…………………………………………………………………………. 
4. Change of antibiotic according to sensitivity pattern:……………………………………… 
5. Duration of  sensitive antibiotic given:…………………………………………………….. 
6. Doasage sensitive antibiotic:………………………………………………………………. 
7. Other ocular medications if any: …………………………………………………………. 
  
FOLLOWUP: 
 
DESCRIPTION OF ULCER:  
VISUAL ACUITY 
(snellen’s chart) 
1st  MONTH 3rd  MONTH 
Right 
Eye 
Left 
Eye 
Right 
Eye 
Left 
Eye 
UCVA 
    
BCVA 
    
DURATION 1st  MONTH 3rd  MONTH 
Size of ulcer 
  
Size of infiltrate or scar 
  
Margins of ulcer 
  
Depth of the ulcer 
  
AC reaction 
  
Size of hypopyon 
  
IMPRESSION: 
1. Time taken for ulcer to heal ( in days)  : 
2. State of ulcer after change of medicine at the end of the study: 
1. Healed 
2. Healing 
3. Perforated 
4. Remained the same  
      3.   Final visual acuity:   
1.Improved   
2.Remained the same  
3. Worsened 
CODING SHEET 
AGE   
SEX   
 MALE 1 
 FEMALE 2 
EYE INVLOVED   
 RIGHT 1 
 LEFT 2 
OCCUPATION   
 AGRICULURIST 1 
 MANUAL LABROURER 2 
 VEGETABLE VENDOR 3 
 CARPENTER 4 
 WHITE COLLAR JOB 5 
 OTHERS 6 
PRESENTING HISTORY   
   
   
   
SYMPTOMS   
 REDNESS 1 
 PHOTOPHOBIA 2 
 WATERING 3 
 PAIN 4 
 BLURRING OF VISION 5 
 IRRITATION 6 
 OTHERS 7 
 NO SYMPTOMS 8 
DURATION   
HISTORY OF TRAUMA   
 DUST 1 
 THORN, THREE BRANCH 2 
 VEGETABLE MATTER 3 
 STICK 4 
 PADDY 5 
 METAL 6 
 STONE 7 
 OTHERS 8 
 NO TRAUMA 9 
HISTORY OF CONTACT 
LENS USAGE 
  
 YES 1 
 NO 2 
TRADITIONAL EYE 
MEDICINE 
  
 HUMAN MILK 1 
 CASTOR OIL 2 
 VEGETABLE JUICE 3 
 OTHERS 4 
 NO TRADITIONAL 
MEDICATION 
5 
   
PREVIOUS OCULAR 
MEDICATION 
  
 ANTIBIOTICS 1 
 ANTIFUNGAL 2 
 ANTIVIRUS 3 
 STEROIDS 4 
 OTHERS 5 
 NO PREVIOUS 
MEDICATION 
6 
PAST OCUALR HISTORY   
 CORNEAL DISEASE 1 
 UVEITIS 2 
 DACROCYSTITIS 3 
 GLAUCOMA 4 
 EYE SURGERIES 5 
 OTHERS 6 
 NIL 7 
SYSTEMIC HISTORY   
 DIABETES 1 
 MALNUTRITION 2 
 IMMUNE SUPPPRESSION 3 
 LEPROSY 4 
 NEUROLOGICAL 
DISORDERS 
5 
 OTHERS 6 
 NONE 7 
RANDOM BLOOD SUGAR   
VISUAL  ACQUITY   
 NO PL 1 
 PL 2 
 HM 3 
 1/60 4 
 2/60 5 
 3/60 6 
 4/60 7 
 5/60 8 
 6/60 9 
 6/36 10 
 6/18 11 
 6/12 12 
 6/9 13 
 6/6 14 
LIDS   
 NORMAL 1 
 EDEMA 2 
 BLEPHARITIS 3 
 TRICHIASIS 4 
 DRY EYE 5 
 LAGOPHTHALMOS 6 
 ENTROPION 7 
 ECTROPION 8 
 OTHERS 9 
CONJUNCTIVA   
 NORMAL 1 
 CONGESTION 2 
 DISCHARGE 3 
 OTHERS 4 
ANTERIOR CHAMBER   
QUIET   
 YES 1 
 NO 2 
AC CELLS   
 0 1 
 0.5+ 2 
 1+ 3 
 2+ 4 
 3+ 5 
 4+ 6 
AC FLARE   
 0 1 
 1+ 2 
 2+ 3 
 3+ 4 
 4+ 5 
HYPOPYON   
 YES 1 
 NO 2 
PUPIL   
 NORMAL 1 
 ABNORMAL 2 
LENS   
 NORMAL 1 
 ABNORMAL 2 
 NO VIEW 3 
FUNDUS   
 DEFERRED 1 
 NORMAL 2 
 ABNORMAL 3 
CORNEAL ULCER   
SITE   
 ENTIRELY IN PERIPHERY 1 
 OVERLAPPING THE 
CORNEAL 4MM CIRCLE 
AND PERIPHERY WITHOUT 
FILLING THE CENTER 
2 
 ENTIRELY IN THE 
CENTRAL 4MM CIRCLE 
3 
 COMPLETELY FILLING 
4MM CIRCLE EXTENDING 
TO PERIPHERY 
4 
SIZE - ED   
INFILTRATE   
 0-33% 1 
 33-67% 2 
 67-100% 3 
 NO 4 
MARGINS OF ULCER   
 REGULAR 1 
 IRREGULAR 2 
STROMAL EDEMA   
 YES 1 
 NO 2 
DM FOLD   
 YES 1 
 NO 2 
CORNEAL SENSATION   
 NORMAL 1 
 DIMINISHED 2 
 ABSENT 3 
IOP BY DIGITAL 
TONOMETRY 
  
 NORMAL  1 
 INCREASED 2 
 DECREASED 3 
DUCT OF AFFECTED EYE   
 FREE 1 
  WITH CLEAR FLUIDS 2 
 WITH PUS 3 
GRAM STAIN   
 GRAM NEGATIVE BACILLI 1 
 GRAM POSITIVE COCCI 2 
 GRAM POSITIVE BACILLI 3 
 NO ORGANISM WITH PUS / 
POLYMORPHS 
4 
 FUNGI  5 
 NOCARDIA 6 
10% KOH   
 POSITIVE 1 
 NEGATIVE 2 
CULTURE REPORT   
 PSEUDOMONAS 
AERUGINOSA 
1 
 STREPTOCOCCUS 
PNEUMONIAE 
2 
 STAPHYLOCOCCUS AERUS 3 
 MRSA 4 
 CONS 5 
 STREPTOCOCCUS 
PYOGENES 
6 
 PSEUDOMONAS SP 7 
 STREPTOCOCCUS 
VIRIDIANS 
8 
 CORNYBACTERIUM 9 
 MOREXELLA SP 10 
 KLEBSIELLA SP 11 
 ACINECTOBACTER SP 12 
 CITROBACTER SP 13 
 HAEMOPHILUS 
INFLUENZA 
14 
 AEROMONAS SP 15 
 PASTURELLA SP 16 
 ENTEROBACTER SP 17 
 BACILLUS SP 18 
 PROPIONIBACTERIUM 19 
 ALCALIGENE 20 
 NOCARDIA 21 
 PROTEUS 22 
 STREPTOCOCCUS + MRSA 23 
ANTIBIOTIC SENSITIVITY   
Levofloxacin   
 S 1 
 I 2 
 R 3 
 ND 4 
gatifloxacin   
 S 1 
 I 2 
 R 3 
 ND 4 
moxifloxacin   
 S 1 
 I 2 
 R 3 
 ND 4 
cephotaxime   
 S 1 
 I 2 
 R 3 
 ND 4 
Gentamicin   
 S 1 
 I 2 
 R 3 
 ND 4 
Tobramycin   
 S 1 
 I 2 
 R 3 
 ND 4 
Ciprofloxacin   
 S 1 
 I 2 
 R 3 
 ND 4 
Amikacin   
 S 1 
 I 2 
 R 3 
 ND 4 
Ofloxacin   
 S 1 
 I 2 
 R 3 
 ND 4 
chloramphenicol   
 S 1 
 I 2 
 R 3 
 ND 4 
cefazolin   
 S 1 
 I 2 
 R 3 
 ND 4 
ceftazidime   
 S 1 
 I 2 
 R 3 
 ND 4 
Cotrimaxazole   
 S 1 
 I 2 
 R 3 
 ND 4 
Vancomycin   
 S 1 
 I 2 
 R 3 
 ND 4 
Norfloxacin   
 S 1 
 I 2 
 R 3 
 ND 4 
Polymixin B   
 S 1 
 I 2 
 R 3 
 ND 4 
Tetracyclin   
 S 1 
 I 2 
 R 3 
 ND 4 
Piperacillin/Tazobactam   
 S 1 
 I 2 
 R 3 
 ND 4 
Cefuroxime   
 S 1 
 I 2 
 R 3 
 ND 4 
TREATMENT   
INITIAL  ANTIMICROBIAL   
 CEFAZOLIN 1 
 MOXIFLOXCIN 2 
 AMIKACIN 3 
 TOBRAMYCIN 4 
 GATIFLOXCIN 5 
 
CHLOROMPHENICOL AND 
POLYMIXCIN B 
6 
 CIPROFLOXCIN 7 
 
CEFAZOLIN + 
CHLORAMPHENICOL + 
POLYMIXCIN B 
8 
 
MOXIFLOXCIN+ 
CHLORAMPHENICOL + 
POLYMIXCIN B 
9 
 
AMIKACIN + 
CHLORAMPHENICOL + 
POLYMIXCIN B 
10 
 
CEFAZOLIN + 
MOXIFLOXCIN 
11 
 
AMIKACIN + 
MOXIFLOXCIN 
12 
 
GATIFLOXCIN + 
CHLORAMPHENICOL + 
POLYMIXCIN B 
13 
   
   
MYDRIATICS   
 YES 1 
 NO 2 
   
ULCER HEALING   
 IMPROVED 1 
 STABLE 2 
 WORSENED 3 
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1 M19881/2015 01-12-2015 P4
17
ALANTHAMMA
L
2 68 2 1 1 1 1 1 1 1 1 3 2 5 1 2 1 8 1 2 1 2 2 1 1 1 2 1 2 2 2 1 1 4 2 1 1 1 2 3 1 2 1 1 1 4 4 1 4 4 1 4 4 2 2 8 1 9 1
2 M19928/2015 01-12-2015 P4
17
SANTHANAM C. 1 61 2 1 1 2 1 1 1 4 8 2 2 5 1 1 1 4 1 3 1 3 2 1 1 1 4 1 2 1 1 3 2 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 2 4 2 6 2
3 M19967/2015 02-12-2015 F1
63
DEVARAJ M. 1 66 1 2 2 2 2 2 2 3 1 1 2 2 3 2 1 8 1 2 1 3 2 1 1 1 2 2 1 1 1 1 8 4 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 1 2 8 1 9 1
4 M19988/2015 02-12-2015 P4
17
KALYANI M. 2 48 1 3 1 2 1 1 1 2 5 3 2 5 3 1 2 8 1 1 2 5 1 1 1 1 2 1 1 2 2 1 9 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 9 1 10 1
5 M19993/2015 02-12-2015 P4
17
MUTHALAGAR R. 1 29 1 6 1 1 1 2 1 4 4 8 1 5 3 2 2 4 2 2 1 4 2 1 1 1 2 3 2 1 1 1 1 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 2 6 2 7 1
6 M20008/2015 02-12-2015 F1
63
MARIYAYEE 2 63 2 1 2 1 2 2 2 6 13 1 2 2 1 1 1 4 1 1 1 5 2 1 1 1 4 3 2 1 1 1 9 1 2 1 1 1 1 2 2 1 1 1 1 4 4 1 4 4 1 4 4 2 3 3 3 3 6
7 M20010/2015 03-12-2015 P2
91
KANDASAMY A. 1 76 1 6 1 2 2 1 1 1 5 1 2 5 2 2 2 10 1 1 1 4 2 1 1 1 2 2 1 1 1 2 1 2 2 2 1 1 1 1 4 4 1 4 1 3 1 4 4 1 4 2 1 1 2 10 1 11 1
8 M20095/2015 04-12-2015 P4
17
PAKKIRI 1 61 2 1 1 2 1 1 1 1 2 2 2 5 3 2 2 11 1 2 1 2 2 1 1 1 1 1 2 2 2 1 2 4 2 5 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 1 4 1 3 8 1 10 2
9 M20129/2015 05-12-2015 P4
17
PALANISAMY P. 1 45 1 6 1 1 1 1 1 4 5 8 2 1 3 2 2 8 1 1 1 2 2 1 1 1 1 1 1 2 2 2 10 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 3 5 1 9 4
10 M20182/2015 07-12-2015 F1
50
MURUGANDI M. 1 57 2 1 2 2 2 2 2 1 2 5 2 2 3 2 2 12 1 2 1 2 2 1 1 1 1 1 1 2 2 1 8 2 2 2 1 1 1 1 3 4 1 4 1 1 1 4 4 1 4 1 4 1 3 9 2 11 2
11 M20409/2015 10-12-2015 F1
63
MANIMEGALAI T. 2 51 1 6 1 1 2 2 1 4 5 2 5 1 2 2 8 1 1 1 2 2 1 1 1 1 1 1 2 2 1 8 4 2 6 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 2 2 8 1 10 2
12 M20537/2015 12-12-2015 F1
63
SANJEEVI 1 71 1 1 2 2 2 2 2 4 1 4 2 5 3 1 2 9 1 2 1 2 2 1 1 1 2 1 1 2 2 1 11 3 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 10 1 10 6
13 M21029/2015 22-12-2015 P4
15
GANESAN P. 1 51 1 1 1 1 1 1 1 3 8 2 2 5 1 2 2 4 1 1 1 3 2 1 1 1 3 2 2 1 1 1 2 1 2 1 1 1 1 2 2 1 1 1 1 3 1 4 4 4 1 3 4 2 2 4 2 7 3
14 M21322/2015 26-12-2015 P4
18
ANJAMMAL R. 2 56 2 1 1 1 1 1 1 3 3 5 2 2 3 2 2 5 1 2 1 3 2 1 1 1 2 3 1 1 1 1 6 2 2 2 1 1 1 1 4 4 2 4 2 1 1 4 4 1 4 1 4 2 2 7 1 9 2
15 M21406/2015 28-12-2015 P4
18
VIRUMANDI V. 1 65 1 1 1 1 1 2 1 1 2 4 2 5 2 2 2 5 1 2 1 2 2 1 1 1 2 1 2 2 2 1 9 1 2 1 1 1 2 1 1 2 1 3 1 4 4 1 4 4 1 4 4 1 2 7 1 10 3
16 M21433/2015 28-12-2015 F1
56
ERUKALAIAH 1 56 1 1 2 1 2 2 2 2 6 3 2 5 1 1 1 3 1 2 1 4 2 1 1 1 3 3 2 1 1 1 3 1 2 1 3 3 3 3 3 4 3 3 3 4 4 3 4 4 1 4 4 2 3 7 2 8 1
17 M21513/2015 29-12-2015 P4
18
SABUR NISHA 
M.
2 51 2 3 1 1 2 1 1 4 4 8 2 5 3 2 2 7 1 2 1 4 2 1 1 1 2 2 1 1 1 1 1 2 2 5 1 1 1 2 3 3 2 4 1 1 2 4 4 1 4 1 4 1 1 8 1 13 5
18 M126/2016 04-01-2016 F1
63
VIRAMALAI R. 1 80 1 1 1 1 1 1 1 6 2 2 2 5 3 2 2 8 1 2 1 2 2 1 1 1 2 1 1 2 2 1 8 2 2 11 1 1 1 1 1 1 1 1 1 1 2 1 4 4 1 1 4 2 3 7 1 10 3
19 M1274/2016 25-01-2016 P4
20
SAGUNTHALA 
K.
2 59 2 6 1 1 1 1 1 2 5 8 2 2 1 1 1 5 1 2 1 5 2 1 1 1 3 3 2 1 1 1 3 5 2 21 3 3 3 1 1 1 3 1 3 1 3 1 3 3 4 4 4 1 2 6 2 8 2
20 M1317/2016 25-01-2016 P4
20
THANSIRA 
BANU
2 38 2 2 1 1 2 2 1 3 5 3 2 5 3 1 1 10 1 2 1 3 2 1 1 1 1 2 1 1 1 1 1 4 2 5 1 1 1 1 1 2 1 1 10 1 11 1
21 M1333/2016 25-01-2016 F1
64
MARUTHAMUT
HU V.
1 40 2 1 1 1 1 1 1 1 2 2 2 5 3 2 2 6 1 2 1 3 2 1 1 1 3 2 1 2 2 1 2 1 2 10 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 1 4 2 3 4 1 9 5
22 M155/2016 04-01-2016 P4
19
NAGAMMAL 2 55 1 1 1 1 1 1 1 1 6 1 2 5 2 2 2 11 1 2 1 3 2 1 1 1 1 1 1 2 2 1 11 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 12 1 12 6
23 M1685/2016 30-01-2016 P4
20
PERIYASAMY A. 1 63 1 2 1 1 1 1 1 1 10 1 2 5 1 2 1 5 1 3 2 5 1 1 1 1 4 2 1 1 1 3 8 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 2 5 3 3 7
24 M1686/2016 30-01-2016 P4
19
PAASAM RAVI 1 47 1 1 2 2 2 2 2 4 9 2 2 2 3 1 2 5 1 1 1 3 2 1 1 1 3 1 2 1 1 2 1 4 2 9 3 3 3 1 3 3 3 4 3 1 1 4 4 1 4 3 4 2 2 6 3 5 7
25 M1708/2016 30-01-2016 P4
20
ALAGARSAMY A. 1 65 1 1 1 1 1 2 1 3 3 2 2 2 3 2 2 8 1 2 1 3 2 1 1 1 3 1 1 2 2 1 8 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 10 1
26 M1711/2016 30-01-2016 P4
20
SAIVARAJ R. 1 56 1 1 2 1 2 2 2 1 1 3 2 5 3 2 2 6 1 2 1 4 2 1 1 1 3 3 2 1 1 1 8 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 2 2 6 3 6 6
27 M423/2016 08-01-2016 F1
63
RAMAN M. 1 80 2 4 2 2 2 2 2 4 3 1 2 5 3 1 2 6 1 2 1 4 2 1 1 1 2 2 2 1 1 1 1 3 2 1 1 1 1 2 2 1 1 1 1 4 4 1 4 4 1 4 4 2 3 6 2 8 2
28 M462/2016 09-01-2016 P3
22
RAMARAJ K. 1 68 1 2 1 1 2 1 1 1 3 1 2 5 3 2 1 8 1 1 1 3 2 1 1 1 2 3 1 1 1 1 9 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 9 1 11 2
29 M561/2016 11-01-2016 P3
48
KARUPPASAMY N. 1 25 1 6 2 1 2 2 2 3 4 1 1 2 1 2 2 11 1 2 1 2 2 1 1 1 2 1 2 2 2 1 2 1 2 10 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 1 4 1 2 12 1 12 6
30 M709/2016 14-01-2016 P4
19
SELVAM S. 1 27 2 6 1 1 1 1 1 4 5 1 2 1 3 2 2 11 1 1 1 3 2 1 1 1 1 2 2 1 1 1 4 1 2 1 1 1 1 3 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 12 1 12 6
31 M714/2016 14-01-2016 P1
73
APPANA SAMY 
S.
1 62 2 1 1 1 1 1 1 2 1 2 2 5 3 2 2 8 1 2 1 3 2 1 1 1 1 1 1 2 2 1 1 4 2 9 1 1 1 1 1 1 2 2 8 1 9 1
32 M76/2016 02-01-2016 F1
63
MAHA KAVI P. 1 32 1 1 1 1 1 2 1 6 4 2 2 5 3 2 2 5 1 2 2 5 1 1 1 1 4 3 1 1 1 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 2 2 5 2 7 2
33 M786/2016 18-01-2016 F1
64
MARIAPPAN S. 1 55 1 2 1 1 2 1 1 4 5 1 2 5 3 1 2 4 1 1 1 3 2 1 1 1 3 2 1 1 1 2 8 4 2 1 1 1 1 2 1 1 1 1 3 4 4 1 4 4 1 3 4 1 2 5 2 8 3
34 M789/2016 18-01-2016 P4
20
RAMANAMMA 
M.
2 48 2 6 1 1 1 1 1 1 6 4 2 5 3 2 2 11 1 2 1 4 2 1 1 1 1 2 1 1 1 1 9 1 2 13 1 1 1 1 1 1 1 1 1 1 2 1 4 4 1 1 4 1 1 12 1 12 6
35 M877/2016 19-01-2016 P4
20
NAIR K.G. 1 77 2 6 1 1 1 2 1 4 3 1 2 2 3 2 2 5 1 2 1 3 2 1 1 1 3 3 1 1 1 1 8 4 2 5 3 3 3 1 1 1 3 4 3 1 1 4 4 1 4 3 4 2 2 7 1 10 3
36 M965/2016 20-01-2016 P4
19
ANNAMMA 
THANAKACHAN
2 70 1 6 1 1 1 1 1 3 4 8 2 5 2 2 2 9 1 2 1 3 2 1 1 1 2 2 2 2 2 1 8 2 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 10 1 10 6
37 M1760/2016 01-02-2016 F1
64
CHENGAL REDDY 
B.
1 75 1 1 1 1 2 2 1 3 5 8 2 5 3 2 2 8 1 1 1 3 2 1 1 1 2 1 1 2 2 3 2 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 1 1 9 1 10 1
38 M1761/2016 01-02-2016 P4
21
MUTHULAKSHMI 
M.
2 54 1 6 1 1 1 1 1 4 5 4 2 5 3 2 2 12 1 2 1 3 2 1 1 1 1 2 1 1 1 1 1 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 12 1 13 1
39 M1778/2016 01-02-2016 P4
21
ALAGAN T. 1 85 2 6 1 1 1 1 1 1 6 2 2 1 2 1 2 6 1 2 1 3 2 1 1 1 3 2 1 1 1 1 11 2 2 2 1 1 1 2 4 4 1 4 1 1 1 4 4 1 4 3 4 2 3 6 2 7 1
40 M1833/2016 01-02-2016 F1
46
INRANI M. 2 52 1 2 1 1 2 2 1 1 1 6 2 5 1 1 2 7 2 2 2 5 1 1 1 1 3 1 1 1 1 1 2 1 2 10 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 3 6 3 5 7
41 M1934/2016 03-02-2016 P4
21
NATCHAMMAL N. 2 55 1 1 1 1 1 1 1 6 4 2 2 5 3 2 2 8 1 2 1 2 2 1 1 1 3 1 2 2 2 1 8 2 2 2 1 1 1 1 1 1 1 1 9 1 10 1
42 M2034/2016 04-02-2016 P2
91
VELUSAMY C. 1 45 1 2 2 2 2 2 2 4 7 1 2 5 1 1 1 6 1 2 2 5 1 1 1 1 3 3 1 1 1 1 10 1 2 14 3 3 3 1 3 3 3 1 3 3 3 1 4 4 1 4 4 2 2 6 2 6 6
43 M2118/2016 05-02-2016 P3
68
VENKATESH V. 1 48 1 2 2 1 2 2 2 1 5 1 2 5 3 2 1 9 1 2 1 3 2 1 1 1 1 1 1 2 2 1 2 2 2 5 1 1 1 3 3 3 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 10 1
44 M2192/2016 06-02-2016 P4
21
RAKKAMMAL 2 45 1 3 1 1 1 2 1 2 5 2 2 5 2 2 2 8 1 2 1 4 2 1 1 1 1 2 1 1 1 1 1 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 9 6
45 M2213/2016 08-02-2016 P4
21
MARAPPAN K. 1 68 2 4 1 1 1 1 1 1 3 1 2 5 3 1 1 3 1 1 1 3 2 1 1 1 4 2 2 1 1 1 1 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 3 2 3 2 6
46 M2716/2016 15-02-2016 F1
64
VELLAIKANNU 
P.
1 69 2 6 1 1 1 1 1 1 5 2 2 5 1 1 1 7 1 2 1 4 2 1 1 1 3 2 1 1 1 1 4 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 2 7 1 9 2
47 M2717/2016 15-02-2016 F1
65
PERIYAKARUPP
AN
1 65 2 1 1 1 1 2 1 4 6 1 2 5 3 1 2 5 1 2 2 5 1 1 1 1 3 3 1 1 1 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 2 2 6 2 8 2
48 M2829/2016 17-02-2016 P4
04
NANDHINI D.S. 2 18 1 6 1 1 1 1 1 3 5 1 2 5 1 2 2 12 1 1 1 3 2 1 1 1 1 1 2 2 2 1 13 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 13 1 13 6
49 M2843/2016 17-02-2016 F1
65
SHINNAIAH M. 1 55 1 2 1 1 1 1 1 6 6 1 2 5 3 1 1 4 1 3 1 3 2 1 1 1 3 1 1 1 1 2 1 4 2 12 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 1 4 1 3 4 3 3 7
50 M3299/2016 24-02-2016 F1
65
THANGARAJ.T 1 69 1 2 2 2 2 2 2 3 4 1 2 5 3 1 1 5 1 2 2 5 1 1 1 1 3 1 2 2 2 1 11 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 2 2 6 1 10 4
51 M3391/2016 26-02-2016 P3
36
MUNIAMMAL 
M.
2 37 2 1 1 1 1 2 1 2 2 4 2 5 3 2 2 7 1 2 1 3 2 1 1 1 2 2 1 1 1 1 2 1 2 1 3 3 3 3 3 3 3 3 3 4 4 3 4 4 1 4 4 1 3 6 2 8 2
52 M3418/2016 26-02-2016 F1
65
ARUMUGAM C. 1 85 1 1 2 1 2 2 2 4 4 2 2 5 3 1 1 8 1 2 1 3 2 1 1 1 2 2 1 2 2 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 10 1 10 6
53 M3501/2016 29-02-2016 P4
19
KARUPPU V. 1 41 1 6 1 1 1 1 1 1 3 1 2 5 3 2 2 10 1 2 1 4 2 1 1 1 1 2 1 1 1 1 8 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 11 1 11 6
54 M3630/2016 01-03-2016 F1
65
SUBBAIAH P. 1 50 2 4 1 1 1 1 1 2 4 1 2 5 3 1 1 6 1 1 2 5 1 1 1 1 4 1 2 2 2 1 1 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 2 7 2 8 1
55 M3739/2016 03-03-2016 P4
23
ESWARAN 1 60 1 2 1 1 1 2 1 4 3 5 2 5 3 1 2 5 1 2 1 4 2 1 1 1 4 2 2 1 1 1 10 4 2 21 3 3 3 1 1 1 3 1 3 1 1 3 3 1 4 4 4 2 3 7 2 9 2
56 M3870/2016 04-03-2016 P4
23
NALLUSAMY 1 65 1 2 1 2 1 1 1 1 8 1 2 5 1 1 1 9 1 1 1 4 2 1 1 1 3 2 1 1 1 3 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 10 1 10 6
57 M4127/2016 09-03-2016 P3
96
SEKAR R. 1 51 2 1 1 1 1 1 1 3 14 9 2 1 3 1 1 6 1 3 1 4 2 1 1 1 2 2 2 1 1 3 8 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 2 7 2 7 6
58 M4206/2016 10-03-2016 P4
23
GURUVAMMAL 
R.
2 55 2 1 1 2 1 1 1 6 3 4 2 5 1 2 2 8 1 2 2 5 1 1 1 1 2 1 1 2 2 1 8 4 2 3 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 1 4 2 3 7 1 9 2
59 M4242/2016 10-03-2016 P3
94
SUBBAIAH K. 1 78 1 6 1 2 1 1 1 4 5 1 2 2 2 1 2 9 1 1 1 3 2 1 1 1 2 2 1 2 2 1 9 4 2 10 1 1 1 1 1 1 1 1 1 1 2 1 4 4 1 1 4 1 1 9 1 9 6
60 M4617/2016 15-03-2016 P4
24
KARTHICK A. 1 14 2 6 1 2 1 1 1 1 15 3 2 5 1 2 2 5 1 1 1 4 2 1 1 1 2 2 2 1 1 1 9 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 3 5 3 5 6
61 M4731/2016 16-03-2016 F1
66
VELLAIAMMAL 
M.
2 70 2 6 2 1 2 2 2 4 3 2 2 5 1 2 2 9 1 2 1 4 2 1 1 1 2 2 2 2 2 1 1 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 1 1 9 1 9 6
62 M5205/2016 24-03-2016 P2
58
ANILKUMAR V. 1 56 1 1 1 1 1 1 1 6 5 1 2 5 3 1 1 4 1 1 1 4 2 1 1 1 3 3 1 1 1 1 9 4 2 1 1 1 1 3 1 1 1 1 1 4 4 1 4 4 1 4 4 1 3 4 2 7 3
63 M5263/2016 25-03-2016 P4
24
VEERASAMY V. 1 60 1 4 2 2 2 2 2 1 5 1 2 5 3 1 1 8 1 1 1 2 2 1 1 1 1 1 1 2 2 3 1 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 9 6
64 M5396/2016 28-03-2016 P4
24
RADHA S. 2 51 1 2 1 2 1 1 1 2 3 3 2 2 3 2 2 6 1 2 1 4 2 1 1 1 3 3 1 1 1 1 4 4 2 3 1 1 1 1 3 3 1 4 1 1 1 4 4 1 4 1 4 2 2 6 2 7 1
65 M5421/2016 28-03-2016 F1
66
KARMEGAM A. 1 65 1 2 2 1 2 2 2 3 10 9 2 5 1 1 2 5 1 2 2 5 1 1 1 1 3 3 2 1 1 1 8 4 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 2 2 7 3 7 6
66 M5489/2016 29-03-2016 F1
64
GANESAN.P 1 50 1 1 2 1 2 2 2 1 5 1 2 5 3 1 1 4 1 2 1 3 2 1 1 1 4 3 1 1 1 1 9 4 2 21 3 3 3 3 1 1 3 1 3 3 3 3 3 3 4 4 4 1 3 3 3 3 6
67 M6054/2016 06-04-2016 P4
25
SYED IBRAHIM 1 65 2 2 1 2 1 1 1 4 3 4 2 5 3 1 2 10 1 2 2 5 1 1 1 1 2 1 1 2 2 1 12 4 2 21 3 1 1 1 3 3 2 1 3 1 3 3 4 3 4 4 4 1 2 11 1 11 6
68 M6103/2016 07-04-2016 P4
19
PREETHIKA M. 2 8 1 6 1 2 1 1 1 1 2 3 2 5 3 2 2 9 1 2 1 4 2 1 1 1 2 2 1 1 1 1 6 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 9 6
69 M6114/2016 07-04-2016 F1
66
MUNIYANDI 1 68 1 1 1 2 1 1 1 3 5 1 2 2 1 1 1 9 1 1 1 3 2 1 1 1 2 2 2 2 2 1 2 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 3 7 1 10 3
70 M6191/2016 08-04-2016 P4
25
PANDI M. 1 42 2 6 1 1 1 1 1 4 1 4 2 5 3 2 2 8 1 2 1 4 2 1 1 1 1 2 1 2 2 1 5 1 2 10 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 1 4 1 1 10 1 10 6
71 M6319/2016 11-04-2016 P4
25
PONNUTHAI 2 55 1 1 1 2 1 1 1 1 1 2 2 5 1 1 1 6 1 2 1 5 2 1 1 1 2 3 2 1 1 1 1 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 2 2 7 2 7 6
72 M6330/2016 11-04-2016 F1
66
ARUMUGAM 1 70 1 2 1 2 1 1 1 6 4 3 2 1 3 1 1 10 1 2 1 3 2 1 1 1 2 2 1 1 1 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 10 1 13 3
73 M6358/2016 12-04-2016 P4
25
VELLAIAN P. 1 69 2 1 2 1 2 2 2 1 1 2 2 5 3 1 1 4 1 2 2 5 1 1 1 1 3 2 1 1 1 1 11 2 2 2 1 4 1 1 1 4 1 4 1 1 1 4 4 1 4 1 4 1 3 5 2 6 1
74 M6492/2016 14-04-2016 P4
25
MARIAPPAN P. 1 33 1 5 1 1 1 1 1 4 5 1 2 2 1 2 2 12 1 2 1 3 2 1 1 1 1 2 1 1 1 1 9 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 13 1 13 6
75 M6496/2016 14-04-2016 F1
62
DHAKSHINAMOO
RTHI P.
1 64 1 2 1 1 1 1 1 3 2 4 2 1 3 1 2 5 1 2 1 3 2 1 1 1 4 1 2 1 1 1 2 1 2 14 1 1 1 3 1 1 1 1 1 4 3 3 4 4 1 3 4 2 2 8 1 9 1
76 M6596/2016 16-04-2016 P4
26
BIJU P.S. 1 35 2 5 1 1 1 1 1 3 2 7 2 5 3 2 2 9 2 2 1 3 2 1 1 1 2 1 1 2 2 1 8 4 2 4 1 1 1 2 3 3 2 4 2 1 2 4 4 1 4 1 4 1 1 10 1 10 6
77 M6622/2016 16-04-2016 F1
66
MAHA LINGAM 
M.
1 49 1 3 1 1 1 1 1 1 7 5 2 5 2 1 1 8 1 2 2 5 1 1 1 1 1 2 1 1 1 1 1 5 2 15 1 1 1 1 1 1 1 2 1 1 3 1 4 4 1 1 4 1 3 7 1 10 3
78 M6816/2016 20-04-2016 F1
66
SUNDARAMOORT
HI S.
1 70 1 6 1 1 1 1 1 4 1 4 2 5 3 1 1 10 1 2 1 2 2 1 1 1 1 1 1 2 2 1 8 3 2 9 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 4 4 1 1 11 1 11 6
79 M6968/2016 22-04-2016 F1
66
RANJITHA R. 2 11 2 6 1 1 1 1 1 1 3 3 2 5 2 2 2 7 1 2 1 3 2 1 1 1 2 2 1 1 1 1 4 1 2 1 1 1 1 2 1 2 1 3 1 4 2 4 4 4 1 4 4 1 1 8 1 10 2
80 M6988/2016 22-04-2016 P4
26
DURAIRAJ . B 1 6 2 6 1 1 1 1 1 1 6 4 2 5 1 2 2 8 1 2 1 3 2 1 1 1 1 2 1 2 2 1 9 1 2 16 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 1 4 1 1 10 1 10 6
81 M8202/2016 11-05-2016 P4
28
NITHIN KUMAR .A 1 3 1 6 1 1 1 1 1 4 8 4 2 2 3 2 2 10 1 3 1 4 2 1 1 1 2 3 2 1 1 2 9 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 2 10 2 10 6
82 M8211/2016 11-05-2016 P4
28
ALAGAMMAL P. 2 70 1 1 1 1 1 1 1 3 4 4 2 5 3 1 2 6 1 2 2 5 1 1 1 1 2 3 2 1 1 1 9 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 3 6 2 9 3
83 M8401/2016 14-05-2016 P1
71
SINGARAVEL 
A.K.A
1 90 2 1 1 1 1 1 1 1 3 4 2 5 3 2 2 6 1 2 1 3 2 1 1 1 3 1 1 2 2 1 1 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 8 1 9 1
84 M8408/2016 14-05-2016 P4
14
KUNJARAM 2 71 2 6 1 1 1 1 1 6 4 2 2 5 3 2 2 8 1 2 1 3 2 1 1 1 2 2 1 1 1 1 8 4 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 1 4 1 1 9 1 10 1
85 M8446/2016 17-05-2016 P4
28
RAJAMMA N. 2 71 1 1 1 1 1 1 1 3 2 5 2 5 3 2 2 11 1 2 1 3 2 1 1 1 2 1 1 2 2 1 2 1 2 13 1 1 1 1 1 1 1 1 1 1 1 1 4 4 1 1 4 1 1 12 1 12 6
86 M9017/2016 25-05-2016 P4
29
RAMAYA NAIDU 
R.
1 82 1 1 1 1 1 1 1 2 8 5 2 5 1 1 1 5 1 3 1 4 2 1 1 1 3 2 2 1 1 3 1 4 2 22 3 3 3 3 3 3 3 3 3 3 3 3 4 4 3 3 4 2 2 7 2 8 1
87 M9076/2016 26-05-2016 P4
26
MARIMUTHU R. 1 40 1 1 1 1 1 1 1 4 3 3 2 5 3 2 2 8 1 2 1 3 2 1 1 1 1 2 2 1 1 1 3 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 3 6 1 9 3
88 M9142/2016 27-05-2016 P4
29
LAKSHMANAN 
C.
1 74 2 1 1 1 1 1 1 1 1 4 2 2 3 2 2 6 1 2 1 3 2 1 1 1 2 3 2 1 1 1 9 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 7 1 10 3
89 M9150/2016 27-05-2016 P4
29
SRINIVASAN V. 1 55 2 2 1 1 1 1 1 3 1 6 2 5 1 2 2 9 1 2 1 3 2 1 1 1 2 2 2 1 1 1 9 4 2 3 1 1 1 1 3 3 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 9 6
90 M9152/2016 27-05-2016 P4
29
PARVATHI N. 2 83 1 6 1 1 1 1 1 4 3 4 2 5 3 2 2 6 1 2 1 5 2 1 1 1 3 3 1 1 1 1 10 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 3 5 2 8 3
91 M9155/2016 27-05-2016 P4
29
PARVATHI N. 2 83 2 6 1 1 1 1 1 2 3 1 2 2 3 2 2 11 1 2 1 4 2 1 1 1 1 2 1 2 2 1 2 2 1 2 1 1 1 1 1 1 1 12 1 12 6
92 M9209/2016 28-05-2016 P4
29
SATHASRI S. 2 1 1 6 1 2 1 1 1 3 2 5 2 5 3 2 2 8 1 2 1 3 2 1 1 1 2 1 1 2 2 1 2 1 2 17 3 3 3 1 1 1 3 3 3 1 1 1 4 4 1 3 4 2 2 9 1 10 1
93 M9212/2016 28-05-2016 F1
68
VALLI P. 2 50 2 1 2 1 2 2 2 3 2 4 2 5 1 1 2 5 1 2 1 3 2 1 1 1 2 3 1 1 1 1 2 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 3 3 1 3 6
94 M9300/2016 30-05-2016 F1
68
SUBBAMMAL C. 2 50 1 2 2 1 2 2 2 1 2 4 2 5 2 1 1 7 1 1 2 5 1 1 1 1 3 2 2 1 1 1 1 2 5 3 3 3 1 3 3 3 4 3 1 1 4 4 1 4 1 4 2 2 7 2 8 1
95 M9361/2016 30-05-2016 P4
29
ALAGARSAMY R. 1 65 1 3 1 2 1 1 1 4 9 1 2 5 3 1 2 6 1 2 1 5 2 1 1 1 3 3 2 1 1 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 1 2 7 2 8 1
96 M9416/2016 31-05-2016 P4
29
RAMAKRISHNAN 
V.
1 75 1 4 2 1 2 2 2 2 12 6 2 2 3 2 2 10 1 1 1 3 2 1 1 1 2 2 1 1 1 2 8 3 2 18 1 1 1 3 1 1 3 4 1 1 3 4 4 1 4 4 4 2 2 10 1 13 3
97 M10512/2016 17-06-2016 F1
69
KAMUTHAI K. 2 75 1 1 1 1 1 1 1 2 5 2 2 5 3 1 2 12 1 1 1 2 2 1 1 1 1 1 1 2 2 1 9 4 2 9 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 4 4 1 1 13 1 13 6
98 M10927/2016 23-06-2016 P4
31
NAGARATHINAM 
M.
1 75 1 2 2 1 2 2 2 3 8 9 2 5 1 2 2 5 1 3 1 4 2 1 1 1 4 3 2 1 1 2 5 1 2 1 1 1 1 2 1 1 1 1 1 4 1 2 4 4 1 4 4 1 2 6 2 6 6
99 M10936/2016 23-06-2016 P4
31
KARUPPAYEE 
R.
2 64 2 3 1 2 1 1 1 1 3 8 2 5 2 2 2 13 1 1 1 3 2 1 1 1 2 1 1 1 1 3 1 2 2 2 1 1 1 1 4 4 1 4 1 3 1 4 4 1 4 1 4 1 1 13 1 13 6
100 M10953/2016 24-06-2016 P4
31
THIRUPPATHY RAJ 
K.
1 10 1 6 1 2 1 1 1 6 2 1 2 2 3 2 2 8 1 2 1 3 2 1 1 1 1 2 1 2 2 1 11 2 2 3 1 1 1 1 3 3 1 4 1 1 1 1 4 1 4 1 4 1 1 9 1 10 1
101 M10997/2016 24-06-2016 F1
69
PANDI V. 1 45 1 6 2 1 2 2 2 4 9 1 2 5 3 2 2 7 1 1 2 5 1 1 1 1 2 3 2 1 1 2 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 3 6 3 6 6
102 M11062/2016 25-06-2016 P4
31
MEENAKSHI M. 2 31 1 6 1 1 1 1 1 2 3 8 1 1 3 2 2 11 1 2 1 3 2 1 1 1 2 1 2 2 2 1 4 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 12 1 12 6
103 M11063/2016 25-06-2016 P4
31
BHARATHA K. 2 40 2 2 2 1 2 2 2 4 2 3 2 5 1 2 2 12 2 2 1 4 2 1 1 1 1 2 1 1 1 1 1 2 2 2 1 1 1 1 4 4 1 4 3 1 1 4 4 1 4 1 4 1 1 13 1 13 6
104 M11985/2016 08-07-2016 P4
29
IMRANKHAN S. 1 18 1 6 1 1 1 1 1 3 2 8 2 5 2 2 1 9 1 3 1 2 2 1 1 1 1 1 1 2 2 3 4 4 2 1 1 1 1 1 1 1 1 1 1 1 4 1 4 4 1 4 4 1 1 10 1 10 6
105 M12171/2016 11-07-2016 P4
32
NATCHAMMAL 
K.
2 70 2 6 2 1 2 2 2 1 5 1 2 5 3 1 2 8 1 2 2 5 1 1 1 1 3 2 1 1 1 1 11 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 2 2 8 2 8 6
106 M12331/2016 13-07-2016 P4
33
THANGA 
VELAMMAL K.
2 60 2 2 2 2 2 2 2 1 1 7 2 5 3 2 2 10 1 2 1 3 2 1 1 1 2 2 1 2 2 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 11 1 11 6
107 M12332/2016 13-07-2016 F1
70
SUDALI MUTHU 
N.
1 82 1 1 1 1 1 1 1 2 5 9 2 5 3 2 2 8 1 1 1 3 2 1 1 1 2 1 1 2 2 3 11 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 1 1 9 1 9 6
108 M12734/2016 19-07-2016 P4
14
VAIYAPURI M. 1 66 1 1 1 1 1 1 1 1 5 4 2 5 3 1 1 7 1 2 1 4 2 1 1 1 3 3 2 1 1 1 1 3 2 9 3 3 3 1 3 3 3 4 3 3 1 4 4 1 4 3 4 1 2 7 3 6 1
109 M12929/2016 21-07-2016 P4
33
POUNAMBAL S. 2 80 1 1 2 2 2 2 2 2 6 1 2 5 2 2 2 7 1 2 1 3 2 1 1 1 2 3 2 1 1 1 9 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 1 4 1 1 9 1 10 1
110 M13256/2016 26-07-2016 P4
33
THRESIAMMA 
JOHN
2 75 2 6 1 1 1 1 1 3 7 8 2 5 3 2 2 10 1 2 1 3 2 1 1 1 2 1 1 1 1 1 8 3 2 9 3 3 3 1 3 3 3 4 3 1 3 4 4 1 4 4 4 1 1 10 1 12 2
111 M13355/2016 27-07-2016 P4
34
KARUPAYEE K. 2 55 1 1 2 1 2 2 2 1 10 2 2 5 3 2 2 12 1 2 1 2 2 1 1 1 1 1 1 2 2 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 1 1 1 13 1 13 6
112 M13410/2016 27-07-2016 P4
33
BALUPILLAI R. 1 65 2 1 2 2 2 2 2 1 4 4 2 5 3 1 1 8 1 2 1 3 2 1 1 1 1 1 1 2 2 1 2 2 2 8 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 1 1 10 1 10 6
113 M14342/2016 08-08-2016 F1
71
ALURI PEDA 
MASTHANAIAH
1 71 1 1 1 1 1 1 1 4 1 4 2 5 3 1 2 5 1 2 2 5 1 1 1 1 3 1 1 1 1 1 1 2 2 6 1 1 1 1 4 4 3 4 3 1 1 4 4 1 4 3 4 2 2 5 1 8 3
114 M14055/2016 03-08-2016 P4
34
ARUMUGAM S. 1 80 1 1 1 1 1 1 1 1 5 3 2 1 3 2 2 9 1 1 1 3 2 1 1 1 1 2 1 1 1 1 2 1 2 1 3 3 3 3 3 3 3 3 3 4 3 3 4 4 4 3 4 2 2 9 2 9 6
115 M14925/2016 16-08-2016 P3
50
GNANAGURUSAM
Y K.
1 71 1 1 2 2 2 2 2 1 1 4 2 5 1 2 2 8 1 2 1 4 2 1 1 1 2 2 1 1 1 1 9 4 2 5 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 10 1
116 M15459/2016 23-08-2016 P4
36
GOMATHI M. 2 6 1 6 2 2 2 2 2 2 7 1 2 5 3 2 2 9 1 2 1 3 2 1 1 1 1 1 2 2 2 1 9 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 3 3 4 1 1 10 1 10 6
117 M14520/2016 10-08-2016 P4
35
KUBENDRAN K. 1 8 2 6 1 1 1 1 1 6 5 5 2 5 3 2 2 13 1 1 1 2 2 1 1 1 2 1 1 2 2 1 8 2 2 8 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 3 4 1 1 13 1 13 6
118 M15801/2016 29-08-2016 F1
59
MALLIKA 2 59 1 6 1 1 1 1 1 4 5 8 2 5 3 2 2 8 1 2 1 3 2 1 1 1 2 3 1 1 1 1 13 1 2 1 3 3 3 3 1 1 3 1 3 4 4 1 4 4 1 4 4 1 1 9 1 9 6
119 M14615/2016 11-08-2016 P4
35
MARIAPPAN M. 1 21 2 4 1 1 1 1 1 1 1 8 1 5 3 2 2 6 2 2 1 4 2 1 1 1 3 2 1 1 1 1 11 3 2 19 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 4 4 1 1 6 1 9 3
120 M14149/2016 04-08-2016 P4
34
MARIMUTHU V. 1 55 1 3 1 1 1 1 1 3 3 3 2 5 1 2 2 9 1 2 1 3 2 1 1 1 2 1 2 2 2 1 8 4 2 1 1 1 1 3 1 1 1 1 1 4 3 1 4 4 1 3 4 1 1 10 1 10 6
121 M15399/2016 23-08-2016 P4
36
MUTHUVELAMM
AL
1 86 1 6 1 1 1 1 1 3 1 7 2 5 3 2 2 6 2 2 1 4 2 1 1 1 2 3 1 1 1 1 2 1 2 12 2 3 3 2 1 3 2 2 6 2 6 6
122 M15730/2016 26-08-2016 P4
36
PALANIYAYEE 2 60 1 1 1 1 1 1 1 1 3 5 2 5 3 2 2 10 1 2 1 3 2 1 1 1 2 1 1 2 2 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 11 1 11 6
123 M14417/2016 09-08-2016 P4
29
PANJAVARNAM P. 2 56 1 2 2 1 2 2 2 2 1 6 2 5 2 2 2 8 2 2 1 3 2 1 1 1 2 2 1 1 1 1 1 2 2 6 1 2 1 1 4 4 3 4 1 1 1 4 4 1 4 3 4 1 1 9 1 9 6
124 M14743/2016 13-08-2016 F1
71
PONNAMMAL L. 2 65 1 2 1 1 1 1 1 4 4 1 2 4 3 2 2 12 1 2 1 2 2 1 1 1 1 1 1 1 1 1 9 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 13 1 13 6
125 M14690/2016 12-08-2016 P4
35
VANITHA S. 2 13 1 6 1 1 1 1 1 1 1 4 2 5 3 2 2 11 1 2 1 3 2 1 1 1 2 1 2 2 2 1 6 3 2 9 3 3 3 1 3 3 3 4 3 1 1 4 4 1 4 4 4 1 1 12 1 12 6
126 M14710/2016 12-08-2016 P4
35
VEERANNA 
THEVAR
1 60 2 3 1 1 1 1 1 2 8 2 2 5 3 2 2 5 1 2 1 3 2 1 1 1 4 2 2 1 1 1 8 2 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 3 4 2 2 9 2 9 6
127 M16127/2016 01-09-2016 P4
36
RAJESWARI P. 2 50 2 2 2 2 2 2 2 3 2 6 2 1 3 2 2 8 2 2 1 2 2 1 1 1 1 1 2 2 2 1 8 4 2 8 1 1 1 2 4 4 3 4 3 1 1 4 4 1 4 1 4 1 1 9 1 9 6
128 M16210/2016 03-09-2016 P4
36
MURUGAN V. 1 49 1 5 1 1 1 1 1 4 7 5 2 5 3 2 2 4 1 1 1 3 2 1 2 1 1 2 2 1 1 1 3 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 2 2 4 2 5 1
129 M16287/2016 05-09-2016 P4
37
LAKSHMI P. 2 48 2 2 1 1 1 1 1 2 5 4 2 5 3 1 1 6 1 2 1 5 2 1 1 1 2 3 1 1 1 1 1 3 2 18 2 3 2 3 1 1 2 4 2 1 3 4 4 3 4 4 4 2 3 5 3 4 7
130 M16752/2016 13-09-2016 P4
37
LAKSHMANAN 
G.
1 77 2 3 1 1 1 1 1 1 4 1 2 5 2 2 2 11 1 1 1 3 2 1 1 1 1 1 1 2 2 3 11 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 12 1 12 6
131 M16772/2016 14-09-2016 P4
34
KANNAN V. 1 41 1 6 1 1 1 1 1 4 8 1 2 4 3 2 2 11 1 1 1 2 2 1 1 1 1 1 1 2 2 1 8 3 2 9 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 1 4 1 1 12 1 12 6
132 M16778/2016 14-09-2016 P3
66
THIRUPATAIAH S. 1 51 1 2 1 1 1 1 1 2 2 7 2 5 3 1 1 5 2 2 1 4 2 1 1 1 3 3 1 1 1 1 11 3 2 2 1 2 1 1 4 4 2 4 2 1 1 4 4 1 4 1 4 1 3 9 1 10 1
133 M17035/2016 19-09-2016 P4
38
LOGAMBAL 2 55 1 2 2 2 2 2 2 1 4 6 2 5 3 1 1 10 1 2 2 5 1 1 1 1 2 1 1 1 1 1 8 2 2 2 1 3 1 1 4 4 3 4 3 1 1 4 4 1 4 1 4 1 1 11 1 11 6
134 M17036/2016 19-09-2016 P4
37
KASI K. 1 58 1 2 1 1 1 1 1 3 6 1 2 5 1 2 2 8 1 1 1 3 2 1 1 1 3 2 2 1 1 1 1 4 2 12 1 1 1 2 1 1 1 1 1 3 3 1 4 4 1 1 4 1 1 10 1 10 6
135 M17185/2016 21-09-2016 P4
38
RAMANAIAH U. 1 65 2 2 1 1 1 1 1 6 4 1 2 4 3 2 2 11 1 2 1 3 2 1 1 1 1 2 1 1 1 1 10 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 3 4 4 1 1 12 1 12 6
136 M17530/2016 26-09-2016 P3
30
PERUMAL K. 1 34 1 4 2 2 2 2 2 1 3 4 2 5 3 2 2 9 1 2 1 4 2 1 1 1 2 2 1 1 1 1 1 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 10 1
137 M18467/2016 07-10-2016 F1
73
YAMA DURGA 
REEDY
1 34 1 1 1 1 1 1 1 1 5 4 2 5 3 2 2 11 1 2 1 3 2 1 1 1 2 1 2 2 2 1 11 3 2 9 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 4 4 1 1 12 1 12 6
138 M18491/2016 07-10-2016 F1
64
MOOKKAIAH K. 1 45 1 1 1 1 1 1 1 2 2 2 2 1 3 2 2 6 1 2 1 4 2 1 1 1 4 3 1 1 1 1 8 3 2 22 3 3 2 1 1 1 3 4 3 3 1 4 4 1 4 4 4 2 2 6 2 6 6
139 M18539/2016 08-10-2016 P2
80
PANDI S. 1 56 1 1 1 1 1 1 1 4 8 1 2 4 1 2 1 7 1 3 1 2 2 1 1 1 3 1 1 2 2 1 2 1 2 7 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 2 7 2 8 1
140 M18575/2016 08-10-2016 F1
55
CHENNIAPPA 
GOUNDER
1 48 2 1 1 1 1 1 1 3 7 2 2 5 3 2 2 11 1 1 2 5 1 1 1 1 1 1 1 2 2 2 11 2 2 2 1 2 1 1 4 4 2 4 2 1 1 4 4 1 4 1 4 1 1 12 1 12 6
141 M18602/2016 10-10-2016 P4
39
VASANTHA R. 2 45 1 3 2 1 2 2 2 1 5 2 2 5 3 1 2 5 1 2 1 3 2 1 1 1 4 1 1 2 2 1 8 2 2 2 1 3 1 1 4 4 2 4 3 1 1 4 4 1 4 1 4 2 2 5 1 9 4
142 M18677/2016 11-10-2016 P2
59
ROOBA V. 2 47 1 3 2 2 2 2 2 1 3 8 2 4 3 1 2 6 1 2 1 4 2 1 1 1 3 2 2 1 1 1 9 1 2 1 3 3 3 3 3 3 3 3 3 4 4 2 4 4 3 4 4 2 3 5 3 5 6
143 M18775/2016 12-10-2016 P4
39
CHINNU 1 43 2 1 1 1 1 1 1 2 7 1 2 5 3 2 2 8 1 1 1 3 2 1 1 1 2 2 2 2 2 1 9 1 2 23 3 3 3 2 3 2 3 4 3 1 1 4 4 2 4 1 4 1 1 9 1 9 6
144 M18988/2016 15-10-2016 P4
11
SAVARI DOSS 
C.
1 44 2 1 1 1 1 1 1 4 1 3 2 5 3 2 2 7 1 2 1 3 2 1 1 1 3 3 1 1 1 1 8 4 2 4 3 3 3 2 2 3 3 4 3 1 2 4 4 2 4 1 4 1 2 8 2 8 6
145 M19062/2016 17-10-2016 P4
40
MANIVEL M. 1 34 1 1 2 2 2 2 2 1 3 3 2 4 1 2 2 10 1 1 1 3 2 1 1 1 1 1 1 2 2 1 1 2 2 4 1 2 1 1 1 4 3 4 3 1 1 4 4 3 4 3 4 1 1 11 1 11 6
146 M19132/2016 18-10-2016 P3
84
MANESH M. 1 58 1 1 1 1 1 1 1 3 5 2 2 5 3 2 2 5 1 2 1 3 2 1 1 1 3 2 1 1 1 1 8 2 2 2 1 2 1 1 4 4 2 4 2 1 4 4 4 1 4 3 4 2 2 5 2 6 1
147 M19157/2016 18-10-2016 F1
73
KADHAR BEEVI 
A.
2 32 2 2 1 1 1 1 1 1 1 6 2 5 3 1 1 4 1 2 1 3 2 1 1 1 2 2 1 1 1 1 2 2 2 2 1 1 1 1 4 4 2 4 1 1 4 4 4 1 4 1 4 1 2 5 2 5 6
148 M19243/2016 19-10-2016 P4
38
PONNAMMAL 
R.
2 65 2 1 1 1 1 1 1 3 8 2 2 5 1 1 2 10 1 2 2 5 1 1 1 1 2 1 2 1 1 1 2 1 2 1 1 1 1 1 1 1 1 2 1 4 1 4 4 4 1 4 4 1 1 11 1 11 6
149 M20118/2016 04-11-2016 P4
41
MUNIYANDI K. 1 70 2 6 2 1 2 2 2 4 1 2 2 4 3 2 2 5 1 2 1 3 2 1 1 1 2 2 2 1 1 1 4 1 2 1 3 3 3 2 3 3 3 3 3 4 4 1 4 4 1 4 4 2 2 5 2 6 1
150 M20288/2016 07-11-2016 P4
29
PALANISAMY C. 1 57 1 2 1 1 1 1 1 4 7 9 2 5 3 2 2 8 1 2 1 2 2 1 1 1 2 1 1 2 2 1 4 1 2 7 1 1 1 1 3 2 1 2 1 4 4 2 4 4 4 1 4 1 1 10 1 10 6
151 M20660/2016 14-11-2016 F1
74
SUBRAMANI 1 61 1 6 2 2 2 2 2 2 15 1 2 5 3 2 2 5 1 2 1 3 2 1 1 1 4 3 1 1 1 1 8 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 3 5 3 4 7
152 M20738/2016 15-11-2016 P4
34
KARUPPAIAH 1 67 2 3 1 2 1 1 1 6 5 1 2 1 3 2 2 9 1 1 1 3 2 1 1 1 2 2 1 1 1 1 5 1 2 1 1 1 1 2 3 3 1 2 1 4 4 1 4 4 3 4 4 1 1 9 1 10 1
153 M20851/2016 16-11-2016 F1
74
CHINNA ALAGI S. 2 70 1 1 2 1 2 2 2 3 2 2 2 4 3 2 1 6 1 2 1 3 2 1 1 1 2 3 1 1 1 1 11 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 4 4 1 4 2 2 6 3 5 7
154 M21173/2016 21-11-2016 P4
42
ABIRAMI S. 2 23 1 6 1 2 1 1 1 4 3 1 1 5 3 2 2 5 1 2 1 3 2 1 1 1 4 2 2 1 1 1 3 1 2 13 1 1 1 1 1 1 1 1 1 1 3 3 4 4 3 3 4 1 1 9 1 12 3
155 M21180/2016 21-11-2016 P4
42
ALAGAN P. 1 68 2 3 1 2 1 1 1 1 5 5 2 5 1 2 2 6 1 1 1 3 2 1 1 1 3 1 1 2 2 1 2 3 2 20 1 1 1 1 1 1 1 1 1 1 1 1 4 4 4 1 4 1 1 6 1 8 2
156 M21328/2016 23-11-2016 P4
42
PERIAKARPAN 1 55 2 4 1 1 1 1 1 4 1 7 2 4 3 2 2 8 2 2 1 3 2 1 1 1 2 1 1 2 2 1 1 4 2 2 1 2 1 1 4 4 2 4 1 1 1 4 4 1 4 1 4 1 1 10 1 10 6
157 M21363/2016 23-11-2016 P2
66
MOHAMED 
SALEEM T.
1 20 1 6 2 2 2 2 2 2 3 4 2 5 3 2 2 9 1 2 1 4 2 1 1 1 1 2 1 2 2 1 10 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 10 1 10 6
158 M21374/2016 23-11-2016 P4
42
HEMA M. 2 42 2 1 1 2 1 1 1 4 4 8 2 5 1 1 1 7 1 2 1 2 2 1 1 1 3 1 2 1 1 1 2 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 1 2 7 1 9 2
159 M21440/2016 24-11-2016 P2
93
SAVITHRIAMMAL 
M.
2 71 1 1 1 1 1 1 1 2 5 3 2 1 3 2 2 8 1 2 1 3 2 1 1 1 4 1 2 1 1 1 9 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 2 2 8 2 8 6
160 M21466/2016 24-11-2016 F1
74
ARUMUGAM 1 39 2 6 2 1 2 2 2 1 2 7 2 4 3 1 1 12 1 2 1 3 2 1 1 1 1 1 1 2 2 1 9 1 2 7 1 1 1 1 2 2 1 2 1 4 4 3 4 4 1 4 4 1 1 13 1 13 6
161 M21639/2016 26-11-2016 F1
62
SORNAM A. 2 63 2 3 1 1 1 1 1 3 6 2 2 5 3 1 1 7 1 1 2 5 1 1 1 1 4 3 2 1 1 1 1 3 2 9 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 4 4 1 2 9 2 9 6
162 M21684/2016 28-11-2016 F1
65
JAYAKRISHNA
N P.
1 57 2 1 1 1 1 1 1 3 2 2 2 4 1 2 2 10 1 2 1 4 2 1 1 1 1 2 1 1 1 1 8 3 2 9 2 3 2 1 1 1 3 4 3 1 1 4 4 1 4 4 4 1 1 11 1 11 6
163 M21792/2016 29-11-2016 F1
61
KARUPPAYEE 
R.
2 56 2 2 2 1 2 2 2 1 4 7 2 5 2 2 2 6 2 1 1 4 2 1 1 1 3 2 2 1 1 1 10 6 2 21 3 3 3 3 3 3 2 1 3 2 3 3 3 1 4 4 4 2 2 6 2 7 1
164 M22554/2016 14-12-2016 P4
41
DHANALAKSHMI 
T.
2 74 1 2 1 1 1 1 1 4 2 4 2 5 3 2 2 10 1 1 2 5 1 1 1 1 1 2 1 1 1 1 13 1 2 1 1 1 1 1 1 1 1 1 1 4 4 1 4 4 1 4 4 1 1 11 1 11 6
165 M22576/2016 14-12-2016 P4
13
PUSHPAM D. 2 71 1 2 1 1 1 1 1 1 1 4 2 4 3 2 2 9 2 2 1 3 2 1 1 1 2 2 1 2 2 1 6 2 2 2 1 1 1 1 4 4 1 4 1 1 1 4 4 1 4 1 4 1 1 9 1 10 1
166 M22891/2016 19-12-2016 P4
44
SUBA LAKSHMI 2 9 1 1 1 1 1 1 1 2 4 1 2 5 2 2 2 9 1 2 1 3 2 1 1 1 1 1 1 2 2 1 9 1 2 10 1 1 1 1 1 1 1 1 1 1 1 1 4 4 3 1 4 1 1 10 1 10 6
167 M23058/2016 21-12-2016 F1
75
ANTONI SAMY 
A.
1 65 2 1 1 2 1 1 1 4 2 4 2 5 1 2 2 8 1 2 1 2 2 1 1 1 2 1 1 2 2 1 8 2 2 2 3 3 3 1 4 4 3 4 3 1 1 4 4 1 4 1 4 1 1 9 1 9 6
168 M24199/2016 23-12-2016 P4
44
NALLAPRAVI 1 45 1 1 1 2 1 1 1 1 3 5 2 5 2 2 2 7 1 3 1 4 2 1 1 1 2 3 2 1 1 3 4 1 2 1 1 1 1 3 3 2 1 2 1 4 4 1 4 4 3 4 4 1 1 8 1 10 2
169 M24341/2016 26-12-2016 F1
75
KALIMUTHAN U. 1 58 1 1 2 1 2 2 2 3 2 4 2 5 3 2 2 10 1 2 1 3 2 1 1 1 2 1 2 2 2 1 11 3 2 9 1 1 1 1 1 1 1 4 1 1 1 4 4 1 4 4 4 1 1 11 1 11 6
170 M24390/2016 26-12-2016 P4
44
MUTHAIAH V. 1 62 1 4 1 1 1 1 1 4 8 1 2 4 1 2 2 5 1 1 1 3 2 1 1 1 4 3 1 1 1 2 1 2 2 2 3 3 2 3 3 1 1 3 3 2 3 2 3 1 1 3 3 2 2 7 2 8 1
171 M24474/2016 27-12-2016 P4
44
LEELAMMA 
JOSEPH
2 67 1 2 1 1 1 1 1 6 2 7 2 5 3 2 2 4 1 2 1 4 2 1 1 1 4 3 1 1 1 1 10 1 2 2 3 3 3 3 3 1 2 2 3 1 1 1 1 2 2 2 3 1 2 4 3 4 6
172 M24485/2016 27-12-2016 P4
44
MARIYA THEPPAS 
S.
1 67 1 3 1 1 1 1 1 3 4 5 2 5 2 2 2 6 2 2 1 2 2 1 1 1 4 1 1 2 2 1 8 4 2 1 3 3 2 1 1 1 3 3 3 3 3 2 1 2 1 3 2 1 1 7 1 10 3
173 M24496/2016 27-12-2016 F1
75
VISALATCHI Y. 2 62 1 2 1 1 1 1 1 1 2 3 2 5 3 1 1 3 1 2 2 5 1 1 1 1 4 2 1 1 1 1 8 3 2 1 1 3 2 2 3 2 2 3 1 2 3 2 2 2 1 3 1 2 2 3 2 3 6
174 M21911/2016 01-12-2016 P4
43
KAMALAM.R 2 70 2 1 1 1 1 1 1 4 5 2 2 4 3 2 2 4 1 2 1 4 2 1 1 1 3 2 1 1 1 1 9 1 2 1 1 1 1 2 1 1 1 1 1 4 4 1 4 4 1 4 4 2 2 5 2 7 2
